Agent for preventing or treating disease associated with accumulation of abnormal protein aggregates

MYPI2025002786A0Undetermined Publication Date: 2024-05-07TANABE PHARMA CORP +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
MYPI2025002786
Authority / Receiving Office
MY · MY
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-07-21
Filing Date
2023-11-07
Publication Date
2024-05-07

AI Technical Summary

Technical Problem

Current therapies lack effective agents to inhibit the accumulation of abnormal protein aggregates, which are associated with neurodegenerative diseases such as frontotemporal lobar degeneration, leading to progressive neurodegeneration and cognitive impairments.

Method used

Development of an RGMa inhibitor, specifically anti-RGMa neutralizing antibodies, which suppress the accumulation of abnormal protein aggregates by inhibiting their uptake into nerve cells and altering actin dynamics, thereby reducing the formation of ubiquitinated protein aggregates.

Benefits of technology

The RGMa inhibitor effectively reduces the accumulation of abnormal protein aggregates, as demonstrated by increased motor neuron preservation and reduced ubiquitinated protein aggregates in animal models, offering a potential therapeutic approach for neurodegenerative diseases like frontotemporal dementia and frontotemporal lobar degeneration.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure PI2025002786_DRAWING_001
    Figure PI2025002786_DRAWING_001
  • Figure PI2025002786_DRAWING_002
    Figure PI2025002786_DRAWING_002
  • Figure PI2025002786_DRAWING_003
    Figure PI2025002786_DRAWING_003
Patent Text Reader

Abstract

Provided is an agent for inhibiting abnormal protein aggregate accumulation or an agent for inhibiting the uptake of an abnormal protein into a neuron, particularly an agent for preventing or treating a disease associated with accumulation of abnormal protein aggregates, in which the agent contains an RGMa inhibiting substance.
Need to check novelty before this filing date? Find Prior Art

Description

Preventive or therapeutic agent for diseases associated with accumulation of abnormal protein aggregates

[0001] The present invention relates to an agent for suppressing the accumulation of abnormal protein aggregates, which comprises an RGMa inhibitor, and particularly to an agent for preventing or treating frontotemporal lobar degeneration.

[0002] Protein quality is controlled within cells by the rapid degradation and removal of misfolded proteins (proteins that do not have the correct three-dimensional structure). However, when genetic or environmental factors (e.g., aging, inflammation, oxidative stress) cause distortions in the protein quality control system, harmful protein aggregates accumulate within cells, contributing to the pathogenesis of various neurodegenerative diseases (Non-Patent Document 1). Furthermore, misfolded protein aggregates can spread between neighboring cells or to distant brain regions via cerebrospinal fluid, leading to the spread of aggregate lesions (Non-Patent Document 2).

[0003] Ubiquitin is one of the tags for misfolded proteins, and harmful protein aggregates that cause neurodegeneration (e.g., aggregates of TDP-43, tau, α-synuclein, and SOD1) are also ubiquitinated (Non-Patent Document 1). Detection of ubiquitin-positive protein aggregates and inclusions in brain autopsies of patients with various neurodegenerative diseases has been reported (Non-Patent Document 3).

[0004] Frontotemporal dementia (FTD) is a group of neurodegenerative disorders characterized by progressive, focal neurodegeneration and atrophy of the frontal and anterior temporal lobes of the brain, resulting in significant behavioral abnormalities, psychiatric symptoms, and language disorders (Non-Patent Document 4). Based on clinical symptoms, FTD is broadly classified into behavioral variant FTD (bvFTD), nonfluent-variant primary progressive aphasia (nfvPPA; progressive nonfluent aphasia, PNFA), and semantic-variant PPA (svPPA; semantic dementia, SD) (Non-Patent Document 4). FTD accompanied by motor neuron disease is called FTD-MND. bvFTD is the most common subtype, accounting for approximately 50% of FTD cases. It typically occurs in adults under 65 years of age and is characterized by severe behavioral, personality, and cognitive impairments.

[0005] Pathologically, FTD is a type of frontotemporal lobar degeneration (FTLD) characterized by the accumulation of inclusion bodies formed by the aggregation of specific proteins in neurons and glial cells. Tau protein, transactive response DNA binding protein of 43 kDa (TDP-43), and fused-in-sarcoma (FUS) proteins have been identified as the major components of these inclusion bodies and are used as a pathological classification (Non-Patent Document 5). Patients in whom tau protein is present among the proteins accumulated in intracellular inclusions are classified as FTLD-tau. Tau protein accumulated in the brains of FTLD-tau patients is known to undergo various post-translational modifications, including hyperphosphorylation, fragmentation, and ubiquitination (Non-Patent Document 6). Tau-negative subtypes are further subdivided, and ubiquitin positivity is also included in the classification criteria for TDP-43-positive FTLD-TDP and FUS-positive FTLD-FUS (Non-Patent Document 5). A clinical-pathological correlation report has shown that more than half of clinically diagnosed bvFTD cases were FTLD-TDP, approximately 70% of nfvPPA (PNFA) cases were FTLD-tau, and approximately 80% of svPPA (SD) cases were FTLD-TDP (Non-Patent Document 7). If the clinical diagnosis is FTD, there is a very high possibility that the underlying pathology includes ubiquitinated protein aggregates.

[0006] RGM (repulsive guidance molecule) is a membrane protein originally identified as an axon guidance molecule in the visual system (Non-Patent Document 8). The RGM family includes three members, termed RGMa, RGMb, and RGMc (Non-Patent Document 9), and it is known that at least RGMa and RGMb function via the same signaling mechanism (Non-Patent Document 10). RGMc plays an important role in iron metabolism. Subsequent research has revealed that RGM functions include axon guidance and lamina formation in Xenopus and chicken embryos, as well as regulating cranial neural tube closure in mouse embryos (Non-Patent Document 11). Patent Document 1 discloses an axon regeneration promoter containing an anti-RGM neutralizing antibody as an active ingredient.

[0007] In addition to its function during development, RGMa is re-expressed after central nervous system injury in adult humans and rats, and RGMa inhibition in rats enhances axonal growth and promotes functional recovery after spinal cord injury (Non-Patent Document 12). Therefore, RGMa is believed to be an inhibitor of axon regeneration after central nervous system injury. Specific antibodies that neutralize RGMa are described, for example, in Patent Document 2 (e.g., 5F9, 8D1), Patent Document 3 (e.g., AE12-1, AE12-1Y), and Patent Document 4 (e.g., r116A3, r70E4, r116A3C, rH116A3). While the role of RGMa in central nervous system injury has been elucidated, the involvement of RGMa in the inhibition of the formation of ubiquitinated aggregates (positive inclusions) has not been identified, and no such therapeutic agent is known.

[0008] International Publication No. WO2005 / 087268 International Publication No. WO2009 / 106356 International Publication No. WO2013 / 112922 International Publication No. WO2016 / 175236

[0009] Watanabe Y, Taguchi K, Tanaka M. Ubiquitin, Autophagy and Neurodegenerative Diseases. Cells. 2020; 9(9):2022.Soto C, Pritzkow S. Protein misfolding, aggregation, and conformational strains in neurodegenerative diseases. Nat Neurosci. 2018 Oct;21(10):1332-1340Chung KK, Dawson VL, Dawson TM. The role of the ubiquitin-proteasomal pathway in Parkinson’s disease and other neurodegenerative disorders. Trends Neurosci. 2001 Nov;24(11 Suppl): 7-14Frontotemporal dementia. Bang J, Spina S, Miller BL.Lancet. 2015 Oct 24;386(10004):1672-82. doi: 10.1016 / S0140-6736(15)00461-4.Review: an update on clinical, genetic and pathological aspects of frontotemporal lobar degenerations. Lashley T, Rohrer JD, Mead S, Revesz T. Neuropathol Appl Neurobiol. 2015 Dec;41(7):858-81. doi: 10.1111 / nan.12250. Epub 2015 Jul 6. PMID: 26041104Mandelkow EM, Mandelkow E. Biochemistry and cell biology of tau protein in neurofibrillary degeneration. Cold Spring Harb Perspect Med 2012; 2: a006247.Therapeutic and diagnostic challenges for frontotemporal dementia. D'Alton S, Lewis J. Front Aging Neurosci. 2014 Aug 19;6:204. doi: 10.3389 / fnagi.2014.00204. eCollection 2014. PMID: 25191265Stahl, B., Muller, B., von Boxberg, Y., Cox, E.C. & Bonhoeffer, F. Biochemical characterization of a putative axonal guidance molecule of the chick visual system. Neuron 5, 735-743 (1990)Muellerら,Philos. Trans. R. Soc. Lond. B Biol. Sci., 361: 1513‐29, 2006Liu, X., Hashimoto, M., Horii, H., Yamaguchi, A., Naito, K. and Yamashita, T. Repulsive guidance molecule b inhibits neurite growth and is increased after spinal cord injury. Biochem. Biophys. Res. Commun. 382, 795-800 (2009)Yamashita, T., Mueller, B.K. & Hata, K. Neogenin and repulsive guidance molecule signaling in the central nervous system. Curr. Opin. Neurobiol.17, 29-34 (2007)Hata, K. et al. RGMa inhibition promotes axonal growth and recovery after spinal cord injury. J. Cell Biol. 173, 47-58 (2006).

[0010] An objective of the present invention is to provide a drug that has an inhibitory effect on the accumulation of abnormal protein aggregates and is effective against diseases associated with the accumulation of abnormal protein aggregates.

[0011] As a result of intensive research to solve the above problems, the present inventors discovered that RGMa inhibitors, particularly anti-RGMa neutralizing antibodies, have the effect of suppressing the accumulation of abnormal protein aggregates and are expected to be effective in treating diseases involving the accumulation of abnormal protein aggregates, leading to the completion of the present invention.

[0012] 1. An inhibitor of abnormal protein aggregate accumulation, which contains an RGMa inhibitor as an active ingredient. 2. An inhibitor of abnormal protein uptake into nerve cells, which contains an RGMa inhibitor as an active ingredient. 3. The agent according to 1 or 2 above, wherein the inhibitor of abnormal protein aggregate accumulation or the inhibitor of abnormal protein uptake into nerve cells is an agent for preventing or treating a disease involving the accumulation of abnormal protein aggregates. 4. 4. The agent according to 3 above, wherein the disease associated with the accumulation of abnormal protein aggregates is selected from spinocerebellar degeneration, spinocerebellar ataxia, dentatorubral-pallidoluysian atrophy, fragile X-associated tremor / ataxia syndrome, spinal-bulbar muscular atrophy, fragile X syndrome, fragile XE syndrome, myotonic dystrophy (type 1), fatal insomnia, frontotemporal dementia or frontotemporal lobar degeneration, Pick's disease, primary progressive aphasia, primary progressive non-fluent aphasia, progressive supranuclear palsy, corticobasal degeneration, argyrophilic grain dementia, glial spheroid inclusion tauopathy, and dementia with Lewy bodies. 5. The agent according to 3 or 4 above, wherein the disease associated with the accumulation of abnormal protein aggregates is frontotemporal dementia (FTD) or frontotemporal lobar degeneration (FTLD). 6. The agent according to any one of 1 to 5 above, wherein the RGMa inhibitor is an anti-RGMa neutralizing antibody. 7. The agent according to 6 above, wherein the anti-RGMa neutralizing antibody is a humanized antibody. 8. The agent according to 6 or 7 above, wherein the anti-RGMa neutralizing antibody is an antibody that recognizes an amino acid sequence selected from SEQ ID NO: 16, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38 and SEQ ID NO: 39. 9. The anti-RGMa neutralizing antibody is selected from the following (a) to (l): (a) an anti-RGMa neutralizing antibody comprising a light chain variable region comprising LCDR1 comprising the amino acid sequence of SEQ ID NO: 5, LCDR2 comprising the amino acid sequence of SEQ ID NO: 6 and LCDR3 comprising the amino acid sequence of SEQ ID NO: 7, and a heavy chain variable region comprising HCDR1 comprising the amino acid sequence of SEQ ID NO: 8, HCDR2 comprising the amino acid sequence of SEQ ID NO: 9 and HCDR3 comprising the amino acid sequence of SEQ ID NO: 10;(b) an anti-RGMa neutralizing antibody comprising a light chain variable region comprising an LCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 11, an LCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 12, and an LCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 13, and a heavy chain variable region comprising an HCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 14, an HCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 15, and an HCDR3 comprising SFG in its amino acid sequence; (c) an anti-RGMa neutralizing antibody comprising a light chain variable region comprising an LCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 17, an LCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 18, and an LCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 19, and a heavy chain variable region comprising an HCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 20, an HCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 21, and an HCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 22; (d) an anti-RGMa neutralizing antibody comprising a light chain variable region comprising an LCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 23, an LCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 24, and an LCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 25, and a heavy chain variable region comprising an HCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 26, an HCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 27, and an HCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 28; (e) an anti-RGMa neutralizing antibody comprising a light chain variable region comprising an LCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 29, an LCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 30, and an LCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 31, and a heavy chain variable region comprising an HCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 32, an HCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 33, and an HCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 34; (f) an anti-RGMa neutralizing antibody comprising a light chain variable region comprising LCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 29, LCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 30, and LCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 35, and a heavy chain variable region comprising HCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 32, HCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 33, and HCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 34;(g) an anti-RGMa neutralizing antibody comprising a light chain variable region comprising LCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 29, LCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 30, and LCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 40, and a heavy chain variable region comprising HCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 32, HCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 33, and HCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 34; (h) an anti-RGMa neutralizing antibody comprising a light chain variable region comprising LCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 29, LCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 30, and LCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 41, and a heavy chain variable region comprising HCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 32, HCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 33, and HCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 34; (i) an anti-RGMa neutralizing antibody comprising a light chain variable region comprising LCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 29, LCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 30, and LCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 42, and a heavy chain variable region comprising HCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 32, HCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 33, and HCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 34; (j) an anti-RGMa neutralizing antibody comprising a light chain variable region comprising LCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 29, LCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 30, and LCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 43, and a heavy chain variable region comprising HCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 32, HCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 33, and HCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 34; (k) an anti-RGMa neutralizing antibody comprising a light chain variable region comprising an LCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 29, an LCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 30, and an LCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 44, and a heavy chain variable region comprising an HCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 32, an HCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 33, and an HCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 34; and(l) The agent according to any one of claims 6 to 8, wherein the agent is an antibody selected from the group consisting of an anti-RGMa neutralizing antibody comprising a light chain variable region comprising an LCDR1 comprising the amino acid sequence set forth in SEQ ID NO:29, an LCDR2 comprising the amino acid sequence set forth in SEQ ID NO:30, and an LCDR3 comprising the amino acid sequence set forth in SEQ ID NO:45, and a heavy chain variable region comprising an HCDR1 comprising the amino acid sequence set forth in SEQ ID NO:32, an HCDR2 comprising the amino acid sequence set forth in SEQ ID NO:33, and an HCDR3 comprising the amino acid sequence set forth in SEQ ID NO:34. 10. A method for preventing or treating a disease associated with the accumulation of abnormal protein aggregates, comprising administering an effective amount of an RGMa inhibitor to a mammal in need of such treatment. 11. The method for preventing or treating a disease associated with the accumulation of abnormal protein aggregates according to claim 10, wherein the RGMa inhibitor is an anti-RGMa neutralizing antibody. 12. Use of an RGMa inhibitor for the manufacture of an agent for preventing or treating a disease associated with the accumulation of abnormal protein aggregates. 13. The use according to claim 12, wherein the RGMa inhibitor is an anti-RGMa neutralizing antibody.

[0013] According to the present invention, an RGMa inhibitor, in particular an anti-RGMa neutralizing antibody, has an effect of suppressing the accumulation of abnormal protein aggregates or an effect of inhibiting the uptake of abnormal proteins into nerve cells, and is useful as an agent for preventing or treating diseases involving the accumulation of abnormal protein aggregates, such as spinocerebellar degeneration, spinocerebellar ataxia, dentatorubral-pallidoluysian atrophy, fragile X-associated tremor / ataxia syndrome, spinal-bulbar muscular atrophy, fragile X syndrome, fragile XE syndrome, myotonic dystrophy (type 1), fatal insomnia, frontotemporal dementia or frontotemporal lobar degeneration, Pick's disease, primary progressive aphasia, primary progressive non-fluent aphasia, progressive supranuclear palsy, corticobasal degeneration, argyrophilic grain dementia, glial cell spherical inclusion tauopathy, or dementia with Lewy bodies.

[0014] Figure 1 shows immunostaining images (photographs) and diagrams demonstrating that anti-RGMa neutralizing antibody (Anti-RGMa Ab; hereafter, the abbreviations in the figures are synonymous) preserves the number of motor neurons with normal morphology in mSOD1 mice. (A) The image is a representative image of motor neurons in the spinal cord of an mSOD1 mouse detected by Nissl staining. The number of anterior horn cells in mSOD1 mice administered with a control antibody (Control Ab; hereafter, the abbreviations in the figures are synonymous) is lower than that in mSOD1 mice administered with an anti-RGMa neutralizing antibody, and anterior horn cells in the mSOD1 mice administered with the control antibody are observed to be atrophied. (B) Quantitative analysis was performed on 15 sections from each individual, each measuring 300 μm 2Neurons containing more than 100 cell bodies were counted as motor neurons. Individual values ​​are plotted and the mean ± standard error is shown. (n = 5 for the control antibody-treated group, n = 5 for the anti-RGMa neutralizing antibody-treated group.) Statistical analysis was performed using Student's t-test. Figure 2 shows spinal cord pathological immunostaining images (photographs) and diagrams demonstrating that anti-RGMa neutralizing antibody treatment reduced ubiquitin-positive protein aggregates in mSOD1 mice. (A) Representative images of motor neurons in the spinal cord of mSOD1 mice detected by ubiquitin staining (scale bar, 300 μm). (B) Quantitative analysis results are shown as the ratio of ubiquitin-positive area to the spinal cord ventral horn area. Individual values ​​are plotted and the mean ± standard error is shown. (n = 3 for the control antibody-treated group, n = 7 for the anti-RGMa neutralizing antibody-treated group.) Statistical analysis was performed using the Mann-Whitney U (MWU) test. Figure 3 (A) and (B) show Western blotting images (photographs) and a diagram showing that cofilin dephosphorylation is elevated in the spinal cord of mSOD1 mice and inhibited by anti-RGMa neutralizing antibodies. The ratio of phosphorylated cofilin to cofilin was determined by quantitative analysis. Individual plots are shown as mean ± standard error. (Wild-type WT, n = 4; control antibody-treated group, n = 5; anti-RGMa neutralizing antibody-treated group, n = 5). Statistical analysis was performed using one-way ANOVA and Tukey's multiple comparisons test. (P-cofilin: phosphorylated cofilin). Figure 3 (C) shows that actin polymerization is reduced in the spinal cord of mSOD1 mice and that this reduction is suppressed by anti-RGMa neutralizing antibodies. Phalloidin staining was used to detect F-actin, and phalloidin-positive motor neurons were counted. Individual plots are shown as mean ± standard error. (Wild type, n = 3; control antibody, n = 4; anti-RGMa neutralizing antibody-treated group, n = 4) Statistical analysis was performed using one-way ANOVA and Tukey's multiple comparisons test. Figure 4(A) shows that RGMa reduces actin polymerization in rat primary cortical neurons, and that this reduction in actin polymerization by RGMa is blocked by anti-RGMa neutralizing antibody.The staining intensity of F-actin and G-actin was quantified for each cell in double immunostained images, and the ratio was calculated as an index of actin polymerization. A total of 36 cells from three wells were analyzed for each evaluation condition. Mean ± standard error is shown. Statistical analysis was performed using one-way ANOVA and Tukey's multiple comparisons test. Figure 4(B) shows that RGMa enhances the entry of mutant SOD1 protein into rat primary cortical neurons. FITC-positive cells were selected from immunostained images of SOD1 protein visualized with an FITC-conjugated anti-FLAG antibody, and the mean signal intensity was quantified. A total of 36 cells selected from three wells for each condition were quantified. Individual plots for each cell are shown as mean ± standard error. Statistical analysis was performed using one-way ANOVA and Tukey's multiple comparisons test. (Jasp: Jasplakinolide) Figure 5 shows that RGMa-enhanced entry of mutant SOD1 protein into rat primary cortical neurons is inhibited by anti-RGMa neutralizing antibodies. FITC-positive cells were selected from immunostained images of SOD1 protein visualized with an FITC-conjugated anti-FLAG antibody, and the mean signal intensity was quantified. A total of 36 cells were selected from three wells for each condition. Individual plots for each cell are shown as mean ± standard error. Statistical analysis was performed using one-way ANOVA and Tukey's multiple comparisons test. Figure 6 shows that RGMa enhances dextran entry into rat primary cortical neurons and is inhibited by anti-RGMa neutralizing antibodies. A total of 36 cells were selected from three wells for each condition, and the mean fluorescence intensity, indicating dextran uptake, was quantified. Individual plots for each cell are shown as mean ± standard error. Statistical analysis was performed using one-way ANOVA and Tukey's multiple comparisons test.Figure 7 shows that RGMa enhances the entry of human tau protein into cells in primary rat cortical neurons, which is inhibited by anti-RGMa neutralizing antibodies. Mean signal intensity was quantitatively analyzed using immunostained images of tau protein visualized with tau antibodies and AlexaFluor™ 594. A total of 36 cells were selected from two independent wells for each condition, and individual plots for each cell are shown as mean ± standard error. Statistical analysis was performed using one-way ANOVA and Tukey's multiple comparisons test. Figure 8 shows that administration of anti-RGMa neutralizing antibodies reduced phosphorylated TDP-43 aggregation in mPFN1 mice. The results of the quantitative analysis (vertical axis) are shown as the ratio of the number of cytoplasmic phosphorylated TDP-43-positive anterior horn cells to the total number of spinal cord anterior horn cells, and are expressed as mean ± standard error (n = 3 for the control antibody group, n = 2 for the anti-RGMa neutralizing antibody group). Statistical analysis was performed using Welch's t-test. Figure 9 shows elevated RGMa concentrations in the cerebrospinal fluid of FTD patients. ANCOVA was used for statistical analysis. In the figure, ND indicates patients with no neurodegenerative disease, and OND indicates patients with other neurodegenerative diseases.

[0015] The terms used in the present invention are explained below. [Neutralization] In this application, neutralization refers to the ability to bind to a target of interest and inhibit any of the functions of that target. For example, an RGMa inhibitor refers to a substance that inhibits the biological activity of RGMa as a result of binding to RGMa.

[0016] Epitope: As used herein, an epitope includes a polypeptide determinant capable of specific binding to an immunoglobulin or T-cell receptor. In certain embodiments, an epitope includes a chemically active surface grouping of a molecule (e.g., amino acids, sugar side chains, phosphoryl or sulfonyl) and, in certain embodiments, may have specific three-dimensional structural characteristics and / or specific charge characteristics. An epitope is the region of an antigen that is bound by an antibody.

[0017] [Isolated] As used herein, the term "isolated" in reference to an isolated RGMa inhibitor (e.g., an antibody) or the like means that it has been identified and separated and / or recovered from components in its natural state. Impurities in its natural state are substances that may interfere with the diagnostic or therapeutic use of the antibody, and include enzymes, hormones, and other proteinaceous or non-proteinaceous solutes. Generally, to isolate an RGMa inhibitor or the like, it is sufficient to purify it by at least one purification step, and an RGMa inhibitor purified by at least one purification step can be referred to as an "isolated RGMa inhibitor."

[0018] [Antibody] In the present application, the term "antibody" broadly refers to an immunoglobulin (Ig) molecule consisting of four polypeptide chains, two heavy chains (H chains) and two light chains (L chains), which substantially retains the epitope-binding property of an Ig molecule.

[0019] [Human antibody] In the present application, a human antibody refers to an antibody in which both the light chain and the heavy chain are derived from human immunoglobulin. Depending on the difference in the heavy chain constant region, human antibodies include IgG (including IgG1, IgG2, IgG3, and IgG4) having a γ heavy chain, IgM having a μ heavy chain, IgA (including IgA1 and IgA2) having an α heavy chain, IgD having a δ heavy chain, or IgE having an ε heavy chain. In principle, the light chain includes either a κ chain or a λ chain.

[0020] [Humanized Antibody] In the present application, a humanized antibody refers to an antibody comprising a variable region consisting of a complementarity determining region of an antibody derived from a non-human animal and a framework region derived from a human antibody, and a constant region derived from a human antibody.

[0021] [Chimeric Antibody] In the present application, a chimeric antibody refers to an antibody in which the light chain, the heavy chain, or both, are composed of a variable region of non-human origin and a constant region of human origin.

[0022] [Monospecific antibody] In the present application, a monospecific antibody is an antibody that has a single antigen specificity and has a single independent antigen recognition site. For example, in this specification, a monospecific antibody that recognizes RGMa may be referred to as an RGMa monospecific antibody.

[0023] [Multispecific antibody] In the present application, a multispecific antibody refers to an antibody that has two or more independent antigen recognition sites with two or more different antigen specificities, and examples include a bispecific antibody that has two antigen specificities and a trispecific antibody that has three antigen specificities.

[0024] [Complementarity-Determining Region (CDR)] Complementarity-determining region (CDR) refers to the region of the variable region of an immunoglobulin molecule that forms the antigen-binding site, also known as a hypervariable region, and refers to the portion where the amino acid sequence varies significantly from one immunoglobulin molecule to another. There are three CDRs in each of the light chain and heavy chain. The three CDRs in the light chain are sometimes referred to as LCDR1, LCDR2, and LCDR3, respectively, and the three CDRs in the heavy chain are sometimes referred to as HCDR1, HCDR2, and HCDR3. For example, the CDRs of an immunoglobulin molecule are determined according to the Kabat numbering system (Kabat et al., 1987 and 1991, Sequences of Proteins of Immunological Interest, US Department of Health and Human Services, NIH, USA). Unless otherwise specified, the present specification uses CDR sequences defined according to the Kabat numbering system. Furthermore, the CDR sequences of SEQ ID NOs: 5 to 15 use CDR sequences defined according to the IMGT numbering system (Lefranc M.-P., Immunology Today 18,509 (1997); Lefranc M.-P., The Immunologist, 7, 132-136 (1999); Lefranc, M.-P., Pommie, C., Ruiz, M., Giudicelli, V., Foulquier, E., Truong, L., Thouvenin-Contet, V., and Lefranc, Dev. Comp. Immunol, 27, 55-77 (2003)). It is obvious to those skilled in the art to replace the CDR sequences described by the IMGT numbering system with any other numbering system, such as the Kabat numbering system. Therefore, embodiments of the present invention include those in which the CDR sequences described by the IMGT numbering system are replaced with the Kabat numbering system, and those in which the CDR sequences described by the Kabat numbering system are replaced with the IMGT numbering system.

[0025] Effective amount: An effective amount refers to the amount of a prophylactic or therapeutic agent sufficient to reduce or ameliorate the severity and / or duration of a disorder or one or more symptoms thereof, prevent progression of a disorder, reverse a disorder, prevent the recurrence, occurrence, onset, or progression of one or more symptoms associated with a disorder, detect a disorder, or enhance or improve one or more prophylactic or therapeutic effects of another treatment (e.g., a prophylactic or therapeutic agent).

[0026] Percent (%) Identity of Amino Acid Sequences: The "percent (%) identity" of an amino acid sequence of a candidate polypeptide sequence, such as a variable region, with respect to the amino acid sequence of a reference polypeptide sequence is defined as the percentage of amino acid residues in the candidate sequence that are identical to the amino acid residues in a particular reference polypeptide sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent identity, and excluding any conservative substitutions from being considered part of the sequence identity. Alignment for purposes of determining percent identity can be achieved by a variety of methods within the skill of those in the art, for example, using publicly available computer software such as BLAST, BLAST-2, ALIGN, or Megalign (DNASTAR) software. Those skilled in the art can determine appropriate parameters for aligning sequences, including any algorithms necessary to achieve maximum alignment over the full length of the sequences being compared. However, for purposes herein, percent identity values ​​are obtained using the sequence comparison computer program BLAST in pairwise alignments. In situations where BLAST is used for amino acid sequence comparison, the percent identity of a given amino acid sequence A to a given amino acid sequence B is calculated as follows: 100 times the fraction X / Y, where X is the number of amino acid residues scored as identical matches by the sequence alignment program BLAST in a program alignment of A and B, and Y is the total number of amino acid residues in B. It will be understood that if the length of amino acid sequence A is different from the length of amino acid sequence B, the percent identity of A to B will differ from the percent identity of B to A. Unless otherwise specified, all percent identity values ​​herein are obtained using the BLAST computer program as set forth in the immediately preceding paragraph.

[0027] Conservative substitution refers to the replacement of an amino acid residue with another chemically similar amino acid residue without substantially altering the activity of the peptide. For example, a hydrophobic residue may be replaced with another hydrophobic residue, or a polar residue may be replaced with another polar residue with the same charge. Examples of functionally similar amino acids that can be substituted in this way include nonpolar (hydrophobic) amino acids such as alanine, valine, isoleucine, leucine, proline, tryptophan, phenylalanine, and methionine. Polar (neutral) amino acids include glycine, serine, threonine, tyrosine, glutamine, asparagine, and cysteine. Positively charged (basic) amino acids include arginine, histidine, and lysine. Negatively charged (acidic) amino acids include aspartic acid and glutamic acid.

[0028] Treatment Treatment includes any treatment of a disease in a subject, preferably a mammal, especially a human, including arresting the progression of the disease and symptoms, eliminating, curing, reducing or alleviating such disease and symptoms.

[0029] [Prevention] Prevention includes preventing or suppressing the onset of the above-mentioned diseases in a subject to be treated, preferably a mammal, particularly a human. Furthermore, "prevention" in the present invention also includes "recurrence prevention," which prevents the recurrence of the above-mentioned diseases that repeatedly undergo remission and relapse in a subject to be treated, preferably a mammal, particularly a human.

[0030] Embodiments of the present invention are described in detail below. The present invention provides a preventive or therapeutic agent for diseases associated with the accumulation of abnormal protein aggregates, which has the effect of inhibiting the accumulation of abnormal protein aggregates, which is a novel use of an RGMa inhibitor. The present invention also provides a preventive or therapeutic method for diseases associated with the accumulation of abnormal protein aggregates, which comprises the step of administering to a mammal in need of treatment an effective amount of a preventive or therapeutic agent containing an RGMa inhibitor.

[0031] <RGMa Inhibitory Substance> The RGMa inhibitor of the present invention may be any substance that acts on RGMa itself and inhibits or attenuates RGMa activity (hereinafter sometimes simply referred to as "RGMa activity" in this specification), and for example, a substance that binds to RGMa and directly inhibits (attenuates) RGMa activity, or that inhibits the binding of RGMa to a receptor and indirectly inhibits (attenuates) RGMa activity (e.g., a compound or antibody described below) is referred to as the RGMa inhibitor of the present invention. The RGMa inhibitor of the present invention may also be a substance that suppresses the expression of RGMa, and for example, a substance that inhibits the expression of RGMa and inhibits (attenuates) RGMa activity (e.g., a nucleic acid molecule described below) is also included in the RGMa inhibitor of the present invention.

[0032] RGMa was identified as a neurite outgrowth inhibitory protein in the central nervous system, and human RGMa protein is biosynthesized as a precursor protein consisting of 450 amino acids as shown in SEQ ID NO: 1. The N-terminal signal peptide Met1 to Pro47 (referring to the peptide from the first methionine residue from the N-terminus to the 47th proline residue, hereinafter the same) is removed, and the peptide bond between Asp168 and Pro169 is cleaved to generate the N-terminal domain. Furthermore, the C-terminal peptide Ala425 to Cys450 of the fragment C-terminal to Pro169 is removed, and a GPI anchor is added to the C-terminal carboxyl group of the resulting C-terminus, Ala424, to generate the C-terminal domain. Human RGMa protein is expressed on the cell membrane via a GPI anchor as a mature protein in which the N-terminal domain (Cys48 to Asp168) and the C-terminal domain (Pro169 to Ala424) are linked by a disulfide bond.

[0033] In the present invention, RGMa may be derived from any animal, but is preferably human RGMa. The precursor protein of human RGMa consists of the amino acid sequence shown in SEQ ID NO: 1 in the sequence listing. The precursor protein of mouse RGMa consists of the amino acid sequence shown in SEQ ID NO: 2 in the sequence listing, and the precursor protein of rat RGMa consists of the amino acid sequence shown in SEQ ID NO: 3 in the sequence listing, but because the C-terminal peptide is removed, the mature proteins have the same amino acid sequence. Examples of RGMa genes include, but are not limited to, the human RGMa gene consisting of the base sequence shown in SEQ ID NO: 4. The base sequences of RGM genes derived from various organisms can be easily obtained from known databases (GenBank, etc.).

[0034] Specific examples of the RGMa inhibitor of the present invention include low molecular weight compounds, anti-RGMa neutralizing antibodies, functionally modified antibodies thereof, conjugated antibodies thereof, or antigen-binding fragments thereof, as well as RGMa nucleic acid molecules such as siRNA (short interfering RNA), shRNA (short hairpin RNA), or antisense oligonucleotides. Of these RGMa inhibitors, preferred are anti-RGMa neutralizing antibodies, functionally modified antibodies thereof, conjugated antibodies thereof, and antigen-binding fragments thereof, more preferred are anti-RGMa neutralizing antibodies or antigen-binding fragments thereof, with anti-RGMa neutralizing antibodies being particularly preferred.

[0035] <Anti-RGMa Neutralizing Antibody> In the present invention, the anti-RGMa neutralizing antibody may be any antibody that binds to RGMa and neutralizes RGMa activity, and may be a polyclonal antibody or a monoclonal antibody. In the present invention, a monoclonal antibody is preferred. Furthermore, the anti-RGMa neutralizing antibody of the present invention may be an RGMa monospecific antibody or a multispecific antibody that recognizes multiple antigens, including RGMa, but is preferably an RGMa monospecific antibody.

[0036] Furthermore, specific epitopes in human RGMa are preferably one or more of SEQ ID NO: 16 (amino acid numbers 47-69 of SEQ ID NO: 1), SEQ ID NO: 36 (amino acid numbers 298-311 of SEQ ID NO: 1), SEQ ID NO: 37 (amino acid numbers 322-335 of SEQ ID NO: 1), SEQ ID NO: 38 (amino acid numbers 349-359 of SEQ ID NO: 1), and SEQ ID NO: 39 (amino acid numbers 367-377 of SEQ ID NO: 1), more preferably the combination of SEQ ID NOs: 36 and 37, and particularly preferably the combination of SEQ ID NOs: 36, 37, and 39.

[0037] The anti-RGMa neutralizing antibodies of the present invention include polyclonal antibodies and monoclonal antibodies obtained by immunizing a mammal such as a mouse with an RGMa protein or a partial fragment thereof (for example, the above-mentioned epitope fragment) as an antigen, chimeric antibodies and humanized antibodies produced using genetic recombination technology, and human antibodies produced using human antibody-producing transgenic animals, etc. When the antibodies of the present invention are administered to humans as pharmaceuticals, humanized antibodies or human antibodies are desirable from the viewpoint of side effects.

[0038] Specific examples of the anti-RGMa neutralizing antibody of the present invention include the following antibodies (a) to (l), and the methods described in Patent Documents 2 to 4 can be used to produce each of them.

[0039] (a) an anti-RGMa neutralizing antibody comprising a light chain variable region comprising an LCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 5, an LCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 6, and an LCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 7, and a heavy chain variable region comprising an HCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 8, an HCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 9, and an HCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 10 (the anti-RGMa neutralizing antibody also includes antibodies having epitopes represented by SEQ ID NOs: 36, 37, and 39); SEQ ID NO: 5: QDISSY SEQ ID NO: 6: YTS (qualifier: mol_type = protein; organism = Mus musculus) SEQ ID NO: 7: QQLNTLPWT SEQ ID NO: 8: GFTFSDAW SEQ ID NO: 9: IRSKANNHAT SEQ ID NO: 10: TRRDGAY

[0040] (b) an anti-RGMa neutralizing antibody comprising a light chain variable region comprising an LCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 11, an LCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 12, and an LCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 13, and a heavy chain variable region comprising an HCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 14, an HCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 15, and an HCDR3 comprising the amino acid sequence AGS (the anti-RGMa neutralizing antibody further includes antibodies having epitopes set forth in SEQ ID NOs: 36, 37, and 38); SEQ ID NO: 11: QSLVHSNGNTY SEQ ID NO: 12: KVS (qualifier: mol_type = protein; organism = Mus musculus) SEQ ID NO: 13: SQSTHVPYT SEQ ID NO: 14: GYSITTSYY SEQ ID NO: 15: ISYDGTN

[0041] (c) an anti-RGMa neutralizing antibody comprising a light chain variable region comprising an LCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 17, an LCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 18, and an LCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 19, and a heavy chain variable region comprising an HCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 20, an HCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 21, and an HCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 22; SEQ ID NO: 17: RSSQSLEYSDGYTFLE SEQ ID NO: 18: EVSNRFS SEQ ID NO: 19: FQATHDPLT SEQ ID NO: 20: NYGMN SEQ ID NO: 21: MIYYDSSEKHYADSVKG SEQ ID NO: 22: GTTPDY

[0042] (d) an anti-RGMa neutralizing antibody comprising a light chain variable region comprising an LCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 23, an LCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 24, and an LCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 25, and a heavy chain variable region comprising an HCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 26, an HCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 27, and an HCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 28, SEQ ID NO: 23: QASQDIDNYLA SEQ ID NO: 24: GATNLAD SEQ ID NO: 25: LQGYIPPRT SEQ ID NO: 26: SYVMH SEQ ID NO: 27: YIIPYNDNTKYNEKFKG SEQ ID NO: 28: ARRNEYYGSSFFDY

[0043] (e) an anti-RGMa neutralizing antibody comprising a light chain variable region comprising an LCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 29, an LCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 30, and an LCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 31, and a heavy chain variable region comprising an HCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 32, an HCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 33, and an HCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 34 (the anti-RGMa neutralizing antibody also includes an antibody having SEQ ID NO: 16 as an epitope); SEQ ID NO: 29: TGTSSSVGDSIYVS SEQ ID NO: 30: DVTKRPS SEQ ID NO: 31: CSYAGTDTL SEQ ID NO: 32: SHGIS SEQ ID NO: 33: WISPYSGNTNYAQKLQG SEQ ID NO: 34: VGSGPYYYMDV

[0044] (f) an anti-RGMa neutralizing antibody comprising a light chain variable region comprising an LCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 29, an LCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 30, and an LCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 35, and a heavy chain variable region comprising an HCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 32, an HCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 33, and an HCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 34 (the anti-RGMa neutralizing antibody also includes an antibody having SEQ ID NO: 16 as an epitope); SEQ ID NO: 29: TGTSSSVGDSIYVS SEQ ID NO: 30: DVTKRPS SEQ ID NO: 35: YSYAGTDTL SEQ ID NO: 32: SHGIS SEQ ID NO: 33: WISPYSGNTNYAQKLQG SEQ ID NO: 34: VGSGPYYYMDV

[0045] (g) an anti-RGMa neutralizing antibody comprising a light chain variable region comprising LCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 29, LCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 30, and LCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 40, and a heavy chain variable region comprising HCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 32, HCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 33, and HCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 34 (the anti-RGMa neutralizing antibody also includes an antibody having SEQ ID NO: 16 as an epitope); SEQ ID NO: 29: TGTSSSVGDSIYVS SEQ ID NO: 30: DVTKRPS SEQ ID NO: 40: FSYAGTDTL SEQ ID NO: 32: SHGIS SEQ ID NO: 33: WISPYSGNTNYAQKLQG SEQ ID NO: 34: VGSGPYYYMDV

[0046] (h) an anti-RGMa neutralizing antibody comprising a light chain variable region comprising LCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 29, LCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 30, and LCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 41, and a heavy chain variable region comprising HCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 32, HCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 33, and HCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 34 (the anti-RGMa neutralizing antibody also includes an antibody having SEQ ID NO: 16 as an epitope); SEQ ID NO: 29: TGTSSSVGDSIYVS SEQ ID NO: 30: DVTKRPS SEQ ID NO: 41: HSYAGTDTL SEQ ID NO: 32: SHGIS SEQ ID NO: 33: WISPYSGNTNYAQKLQG SEQ ID NO: 34: VGSGPYYYMDV

[0047] (i) an anti-RGMa neutralizing antibody comprising a light chain variable region comprising LCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 29, LCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 30, and LCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 42, and a heavy chain variable region comprising HCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 32, HCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 33, and HCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 34 (the anti-RGMa neutralizing antibody also includes an antibody having SEQ ID NO: 16 as an epitope); SEQ ID NO: 29: TGTSSSVGDSIYVS SEQ ID NO: 30: DVTKRPS SEQ ID NO: 42: LSYAGTDTL SEQ ID NO: 32: SHGIS SEQ ID NO: 33: WISPYSGNTNYAQKLQG SEQ ID NO: 34: VGSGPYYYMDV

[0048] (j) an anti-RGMa neutralizing antibody comprising a light chain variable region comprising LCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 29, LCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 30, and LCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 43, and a heavy chain variable region comprising HCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 32, HCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 33, and HCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 34 (the anti-RGMa neutralizing antibody also includes an antibody having SEQ ID NO: 16 as an epitope); SEQ ID NO: 29: TGTSSSVGDSIYVS SEQ ID NO: 30: DVTKRPS SEQ ID NO: 43: VSYAGTDTL SEQ ID NO: 32: SHGIS SEQ ID NO: 33: WISPYSGNTNYAQKLQG SEQ ID NO: 34: VGSGPYYYMDV

[0049] (k) an anti-RGMa neutralizing antibody comprising a light chain variable region comprising an LCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 29, an LCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 30, and an LCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 44, and a heavy chain variable region comprising an HCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 32, an HCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 33, and an HCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 34 (the anti-RGMa neutralizing antibody also includes an antibody having SEQ ID NO: 16 as an epitope), and

[0050] (l) An anti-RGMa neutralizing antibody comprising a light chain variable region comprising an LCDR1 comprising the amino acid sequence set forth in SEQ ID NO:29, an LCDR2 comprising the amino acid sequence set forth in SEQ ID NO:30, and an LCDR3 comprising the amino acid sequence set forth in SEQ ID NO:45, and a heavy chain variable region comprising an HCDR1 comprising the amino acid sequence set forth in SEQ ID NO:32, an HCDR2 comprising the amino acid sequence set forth in SEQ ID NO:33, and an HCDR3 comprising the amino acid sequence set forth in SEQ ID NO:34 (the anti-RGMa neutralizing antibody also includes an antibody having an epitope of SEQ ID NO:16), such as an antibody selected from the following: SEQ ID NO:29: TGTSSSVGDSIYVS SEQ ID NO:30: DVTKRPS SEQ ID NO:45: KSYAGTDTL SEQ ID NO:32: SHGIS SEQ ID NO:33: WISPYSGNTNYAQKLQG SEQ ID NO:34: VGSGPYYYMDV. Among these, particularly preferred is the antibody set forth in (a).

[0051] Furthermore, examples of the anti-RGMa neutralizing antibody of the present invention include the antibodies described in WO2016 / 175236, WO2009 / 106356, and WO2013 / 112922, and the antibodies described in these publications are also included in the anti-RGMa neutralizing antibody of the present invention. Specifically, examples of the anti-RGMa neutralizing antibody of the present invention include antibodies selected from the following (a') to (i'):

[0052] (a') An anti-RGMa neutralizing antibody comprising a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 46 and a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 47, SEQ ID NO: 46: DIQMTQSPSSVSASVGDRVTITCRASQDISSYLNWYQQKPGKAPKLLIYYTSRLHSGVPSRFSGSGSGTDFTLTISSLQPEDFASYFCQQLNTLPWTFGGGTKVEME SEQ ID NO: 47: EVQLVESGGGLVQPGRSLRLSCTASGFTFSDAWMDWVRQAPGKGLEWVAEIRSKANNHATYYAESVKGRFTISRDDSKSIVYLQMNSLRTEDTALYYCTRRDGAYWGKGTTVTVSS

[0053] (b') An anti-RGMa neutralizing antibody comprising a light chain comprising the amino acid sequence set forth in SEQ ID NO: 48 and a heavy chain comprising the amino acid sequence set forth in SEQ ID NO: 49. SEQ ID NO: 48: DIQMTQSPSSVSASVGDRVTITCRASQDISSYLNWYQQKPGKAPKLLIYYTSRLHSGVPSRFSGSGSGTDFTLTISSLQPEDFASYFCQQLNTLPWTFGGGTKVEMERTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC SEQ ID NO: 49: EVQLVESGGGLVQPGRSLRLSCTASGFTFSDAWMDWVRQAPGKGLEWVAEIRSKANNHATYYAESVKGRFTISRDDSKSIVYLQMNSLRTEDTALYYCTRRDGAYWGKGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSC DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIE KTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

[0054] (c') An anti-RGMa neutralizing antibody comprising a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 50 and a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 51, SEQ ID NO: 50: DVVMTQTPLSLPVSLGDQASISCRSSQSLVHSNGNTYLHWYLQRPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGLYFCSQSTHVPYTFGGGTKLEIK SEQ ID NO: 51: DVKLQESGPGLVKPSQSLSLTCSVTGYSITTSYYWNWIRQFPGNKLEWMGYISYDGTNNYNPSLKNRISITRDTSKNQFFLRLNSVTTEDTATYYCAGSFGYSQGTLVTVSA

[0055] (d') an anti-RGMa neutralizing antibody comprising a light chain comprising the amino acid sequence set forth in SEQ ID NO: 52 and a heavy chain comprising the amino acid sequence set forth in SEQ ID NO: 53, SEQ ID NO: 52: DVVMTQTPLSLPVSLGDQASISCRSSQSLVHSNGNTYLHWYLQRPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGLYFCSQSTHVPYTFGGGTKLEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEYERHNSYTCEATHKTSTSPIVKSFNRNEC SEQ ID NO: 53: DVKLQESGPGLVKPSQSLSLTCSVTGYSITTSYYWNWIRQFPGNKLEWMGYISYDGTNNYNPSLKNRISITRDTSKNQFFLRLNSVTTEDTATYYCAGSFGYSQGTLVTVSAAKTTPPSVYPLAPGCGDTTGSSVTLGCLVKGYFPESVTVTWNSGSLSSSVHTFPALLQSGLYTMSSSVTVPSSTWPSQTVTCSVAHPASSTTVDKKLEPSGPISTINP CPPCKECHKCPAPNLEGGPSVFIFPPNIKDVLMISLTPKVTCVVVDVSEEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTIRVVSTLPIQHQDWMSGKEFKCKVNNKDLPSPIE RTISKIKGLVRAPQVYILPPPAEQLSRKDVSLTCLVVGFNPGDISVEWTSNGHTEENYKDTAPVLDSDGSYFIYSKLNMKTSKWEKTDSFSCNVRHEGLKNYYLKKTISRSPGK

[0056] (e') An anti-RGMa neutralizing antibody comprising a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 54 and a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 55. SEQ ID NO: 54: DVVLTQTPVSLSVTLGDQASMSCRSSQSLEYSDGYTFLEWFLQKPGQSPQLLIYEVSNRFSGVPDRFIGSGSGTDFTLKISRVEPEDLGVYYCFQATHDPLTFGSGTKLEIKR SEQ ID NO: 55: EVQLVESGGGLVQPGSSLKLSCVASGFTFSNYGMNWIRQAPKKGLEWIGMIYYDSSEKHYADSVKGRFTISRDNSKNTLYLEMNSLRSEDTAIYYCAKGTTPDYWGQGVMVTVSS

[0057] (f') An anti-RGMa neutralizing antibody comprising a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 56 and a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 57, SEQ ID NO: 56: DIQMTQSPASLSASLEEIVTITCQASQDIDNYLAWYHQKPGKSPRLLIYGATNLADGVPSRFSGSRSGTQFSLKINRLQIEDLGIYYCLQGYIPPRTFGGGTKLELKR SEQ ID NO: 57: EVQLQQSGPELVKPGTSVKMSCKTSGYTFTSYVMHWVKQKPGQGLEWIGYIIPYNDNTKYNEKFKGKATLTSDKSSSTAYMELSSLTSEDSAVYYCARRNEYYGSSFFDYWGQGTTLTVSS

[0058] (g') An anti-RGMa neutralizing antibody comprising a light chain variable region (lambda chain) comprising the amino acid sequence set forth in SEQ ID NO: 58 and a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 59, SEQ ID NO: 58: QSALTQPRSVSGSPGQSVTISCTGTSSSVGDSIYVSWYQQHPGKAPKLMLYDVTKRPSGVPDRFSGSKSGNTASLTISGLQAEDEADYYCCSYAGTDTLFGGGTKVTVL SEQ ID NO: 59: EVQLVQSGAEVKKPGASVKVSCKASGYTFTSHGISWVRQAPGQGLDWMGWISPYSGNTNYAQKLQGRVTMTTDTSTSTAYMELSSLRSEDTAVYYCAR VGSGPYYYMDVWGQGTLVTVSS

[0059] (h') an anti-RGMa neutralizing antibody comprising a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 60 and a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 59; and SEQ ID NO: 60: QSALTQPRSVSGSPGQSVTISCTGTSSSVGDSIYVSWYQQHPGKAPKLMLYDVTKRPSGVPDRFSGSKSGNTASLTISGLQAEDEADYYCYSYAGTDTLFGGGTKVTVL SEQ ID NO: 59: EVQLVQSGAEVKKPGASVKVSCKASGYTFTSHGISWVRQAPGQGLDWMGWISPYSGNTNYAQKLQGRVTMTTDTSTSTAYMELSSLRSEDTAVYYCAR VGSGPYYYMDVWGQGTLVTVSS

[0060] (i') An anti-RGMa neutralizing antibody comprising a light chain comprising the amino acid sequence set forth in SEQ ID NO: 61 and a heavy chain comprising the amino acid sequence set forth in SEQ ID NO: 62. SEQ ID NO: 61: QSALTQPRSVSGSPGQSVTISCTGTSSSVGDSIYVSWYQQHPGKAPKLMLYDVTKRPSGVPDRFSGSKSGNTASLTISGLQAEDEADYYCYSYAGTDTLFGGGTKVTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS SEQ ID NO: 62: EVQLVQSGAEVKKPGASVKVSCKASGYTFTSHGISWVRQAPGQGLDWMGWISPYSGNTNYAQKLQGRVTMTTDTSTSTAYMELSSLRSEDTAVYYCARVGSGPYYYMDVWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPK SCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDQLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPI EKTISKAKGQPREPQVYTLPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVLHEALHNHYTQKSLSLSPGK

[0061] The anti-RGMa neutralizing antibody of the present invention can be produced by an existing commonly used production method. The antigen may be used for immunization as is, or may be used as a complex with a carrier protein. Condensing agents such as glutaraldehyde, carbodiimide, and maleimide active ester can be used to prepare the complex of antigen and carrier protein. Examples of carrier proteins include bovine serum albumin, thyroglobulin, hemocyanin, and KLH.

[0062] Mammals to be immunized include mice, rats, hamsters, guinea pigs, rabbits, cats, dogs, pigs, goats, horses, and cows, and inoculation methods include subcutaneous, intramuscular, and intraperitoneal administration. The vaccine may be administered in a mixture with complete or incomplete Freund's adjuvant, and is typically administered once every 2 to 5 weeks. Antibody-producing cells obtained from the spleen or lymph nodes of immunized animals are fused with myeloma cells and isolated as hybridomas. Myeloma cells derived from mammals, such as mice, rats, and humans, are used.

[0063] <Polyclonal antibodies> Polyclonal antibodies can be obtained, for example, by immunizing a mammal such as those described above with the antigen, together with Freund's adjuvant as necessary, and then obtaining the serum from the immunized animal.

[0064] <Monoclonal Antibodies> Monoclonal antibodies can be obtained specifically as follows. That is, an antigen such as those described above is used as an immunogen, and the immunogen, together with Freund's adjuvant, if necessary, is injected subcutaneously, intramuscularly, intravenously, into the footpad, or intraperitoneally into a mammal such as those described above, or the immunogen is implanted therein, one to several times, to immunize the mammal. Usually, immunization is performed one to four times at intervals of about 1 to 14 days after the initial immunization, and antibody-producing cells are obtained from the immunized mammal about 1 to 5 days after the final immunization.

[0065] Monoclonal antibodies can be obtained using methods well known to those skilled in the art (e.g., Current Protocols in Molecular Biology (John Wiley & Sons (1987)); Antibodies: A Laboratory Manual, Ed. Harlow and David Lane, Cold Spring Harbor Laboratory (1988)).

[0066] Hybridomas secreting monoclonal antibodies can be prepared according to the method of Kohler and Milstein et al. (Nature, 256, 495, 1975) or modifications thereof. Specifically, hybridomas are prepared by fusing antibody-producing cells contained in the spleen or other tissues obtained from an immunized mammal with myeloma cells derived from a mammal, preferably a mouse, rat, or human, that are not capable of producing autoantibodies.

[0067] Examples of myeloma cells that can be used in cell fusion include mouse-derived myeloma P3 / X63-AG8.653 (653), P3 / NSI / 1-Ag4-1 (NS-1), P3 / X63-Ag8.U1 (P3U1), SP2 / 0-Ag14 (Sp2 / 0, Sp2), PAI, F0, or BW5147, rat-derived myeloma 210RCY3-Ag.2.3, and human-derived myeloma U-266AR1, GM1500-6TG-A1-2, UC729-6, CEM-AGR, D1R11, or CEM-T15.

[0068] Examples of fusion promoters include polyethylene glycol, and cell fusion can be achieved by reacting polyethylene glycol (average molecular weight 1000 to 4000) at a concentration of about 20 to 50%, at a temperature of 20 to 40°C, preferably 30 to 37°C, at a ratio of antibody-producing cells to myeloma cells of usually about 1:1 to 10:1, for about 1 to 10 minutes.

[0069] Hybridoma clones that produce monoclonal antibodies can be screened by culturing the hybridomas, for example, in a microtiter plate and measuring the reactivity of the culture supernatant in the wells against the immunizing antigen by an immunochemical method such as ELISA.

[0070] In screening for antibody-producing hybridomas, in addition to a binding assay with RGMa protein, an evaluation is also performed to determine whether the antibody inhibits the RGMa activity of the present invention. These screening methods allow the selection of anti-RGMa neutralizing antibodies of the present invention.

[0071] Clones can be obtained from wells containing hybridomas that produce the desired antibody by limiting dilution. Hybridoma selection and breeding are usually carried out in an animal cell medium containing 10-20% fetal bovine serum and supplemented with HAT (hypoxanthine, aminopterin, thymidine).

[0072] Monoclonal antibodies can be produced from hybridomas by culturing the hybridomas in vitro or by growing them in vivo, for example, in ascites of a mammal such as a mouse or rat, and isolating the antibodies from the resulting culture supernatant or from the ascites of the mammal.

[0073] When culturing in vitro, a nutrient medium suitable for growing, maintaining, and preserving hybridomas and producing monoclonal antibodies in the culture supernatant can be used, depending on various conditions such as the characteristics of the cell type being cultured and the culture method, etc. Examples of the nutrient medium include known nutrient media and nutrient media prepared from basal media.

[0074] Examples of basal media include low-calcium media such as Ham's F12 medium, MCDB153 medium, and low-calcium MEM medium, and high-calcium media such as MCDB104 medium, MEM medium, D-MEM medium, RPMI1640 medium, ASF104 medium, and RD medium. The basal media may contain, for example, serum, hormones, cytokines, and / or various inorganic or organic substances, depending on the purpose.

[0075] Monoclonal antibodies can be isolated and purified by subjecting the culture supernatant or ascites fluid described above to saturated ammonium sulfate, euglobulin precipitation, caproic acid method, caprylic acid method, ion exchange chromatography (DEAE or DE52, etc.), or affinity column chromatography such as an anti-immunoglobulin column or protein A column. Specifically, monoclonal antibodies can be purified using known immunoglobulin purification methods, and can be easily achieved by, for example, ammonium sulfate fractionation, PEG fractionation, ethanol fractionation, the use of an anion exchanger, or affinity chromatography using RGMa protein.

[0076] Monoclonal antibodies can also be obtained by phage display. In phage display, phages selected from a phage antibody library are screened with the target immunogen, and phages with the desired binding affinity to the immunogen are selected. Next, the antibody-corresponding sequence contained in the phage is isolated or sequenced, and an expression vector containing a nucleic acid molecule encoding the antibody or antigen-binding domain is constructed based on the isolated or sequence information. Monoclonal antibodies can then be produced by culturing a cell line transfected with such an expression vector. Human antibodies with the desired binding affinity can be generated by using a human antibody library as the phage antibody library.

[0077] <Nucleic Acid Molecules> Nucleic acid molecules encoding the anti-RGMa neutralizing antibodies or antigen-binding fragments thereof of the present invention can be obtained, for example, by the following method. First, total RNA is prepared from cells such as hybridomas using a commercially available RNA extraction kit, and cDNA is synthesized using reverse transcriptase with random primers or the like. Next, the cDNA encoding the antibody is amplified by PCR using oligonucleotides with sequences conserved in the variable regions of known human antibody heavy chain and light chain genes as primers. The sequence encoding the constant region can be obtained by amplifying a known sequence by PCR. The base sequence of the DNA can be determined by conventional methods, such as by incorporating it into a sequencing plasmid. Alternatively, DNA encoding the monoclonal antibody of the present invention can be obtained by chemically synthesizing the sequence of the variable region or a portion thereof and linking it to a sequence containing the constant region. The nucleic acid molecule may encode all of the constant and variable regions of the heavy and light chains, or it may encode only the variable regions of the heavy and light chains. When encoding both the constant and variable regions, the nucleotide sequences of the heavy and light chain constant regions are preferably those described in Nucleic Acids Research, vol. 14, p. 1779, 1986; The Journal of Biological Chemistry, vol. 257, p. 1516, 1982; and Cell, vol. 22, p. 197, 1980.

[0078] <Functionally Modified Antibodies> Functionally modified anti-RGMa neutralizing antibodies can be prepared by the following methods. For example, when the present anti-RGMa neutralizing antibodies are produced using CHO cells in which the α1,6-fucosyltransferase (FUT8) gene has been disrupted as host cells, antibodies with reduced fucose content in the sugar chains and enhanced cell-killing activity are obtained, and when produced using CHO cells into which the FUT8 gene has been introduced as host cells, antibodies with reduced cell-killing activity are obtained (WO 2005 / 035586, WO 2002 / 31140, WO 00 / 61739). Furthermore, complement activation function can be regulated by modifying amino acid residues in the Fc region (U.S. Patent No. 6,737,056, U.S. Patent No. 7,297,775, U.S. Patent No. 7,317,091). Furthermore, the use of Fc region mutants that enhance binding to FcRn, one of the Fc receptors, can extend the blood half-life (Hashiguchi Shuhei et al., Biochemistry, 2010, Vol. 82(8), p. 710). These functionally modified antibodies can be produced by genetic engineering. The use of Fc region mutants that enhance binding to FcRn, one of the Fc receptors, can extend the blood half-life (Hashiguchi Shuhei et al., Biochemistry, 2010, Vol. 82(8), p. 710). These functionally modified antibodies can be produced by genetic engineering.

[0079] <Conjugate Antibody> Examples of modified molecules of the anti-RGMa neutralizing antibody of the present invention include conjugate antibodies. Examples of conjugate antibodies include conjugated anti-RGMa neutralizing antibodies chemically or genetically bound to functional molecules other than the anti-RGMa neutralizing antibody of the present application, such as non-peptide polymers such as polyethylene glycol (PEG), radioactive substances, toxins, low-molecular-weight compounds, cytokines, growth factors (TGF-β, NGF, Neurotrophin, etc.), albumin, enzymes, and other antibodies.

[0080] When PEG is attached as a functional molecule, PEG can have a molecular weight of, but not limited to, 2,000 to 100,000 Da, more preferably 10,000 to 50,000 Da, and can be either linear or branched. PEG can be attached to the N-terminal amino group of an amino acid of an anti-RGMa neutralizing antibody, for example, by using an NHS active group.

[0081] When a radioactive substance is used as a functional molecule, 131 I, 125 I, 90 Y. 64 Cu, 99 Tc, 77 Lu or 211 Radioactive substances can be directly bound to anti-RGMa neutralizing antibodies by the chloramine T method or the like.

[0082] When a toxin is used as a functional molecule, bacterial toxins (eg, diphtheria toxin), plant toxins (eg, ricin), low-molecular-weight toxins (eg, geldanamycin), maytansinoids, calicheamicin, and the like can be used.

[0083] When a low molecular weight compound is used as the functional molecule, examples thereof include daunomycin, doxorubicin, metrorexate, mitomycin, neocarzinostatin, vindesine, and fluorescent dyes such as FITC.

[0084] When an enzyme is used as the functional molecule, luciferase (e.g., firefly luciferase and bacterial luciferase; U.S. Pat. No. 4,737,456), malate dehydrogenase, urease, peroxidase (e.g., horseradish peroxidase (HRPO)), alkaline phosphatase, β-galactosidase, glucoamylase, lysozyme, saccharide oxidase (e.g., glucose oxidase, galactose oxidase, and glucose-6-phosphate dehydrogenase), heterocyclic oxidase (e.g., uricase and xanthine oxidase), lactoperoxidase, microperoxidase, etc. may be used.

[0085] Linkers used to chemically link toxins, small molecules, or enzymes include divalent radicals (e.g., alkylene, arylene, heteroarylene), -(CR) n O (CR2) n Examples of suitable linkers include linkers represented by - (R is an optional substituent, and n is a positive integer), repeating alkoxy units (e.g., polyethyleneoxy, PEG, polymethyleneoxy, etc.), alkylamino (e.g., polyethyleneamino, Jeffamine™), and diacid esters and amides (succinate, succinamide, diglycolate, malonate, caproamide, etc.). Chemical modification methods for attaching functional molecules have already been established in the field (DJ King., Applications and Engineering of Monoclonal Antibodies., 1998 TJ International Ltd; Monoclonal Antibody-Based Therapy of Cancer., 1998 Marcel Dekker Inc; Chari et al., Cancer Res., 1992 Vol. 152:127; Liu et al., Proc Natl Acad Sci USA., 1996 Vol. 93:8681).

[0086] <Antigen-binding fragment> In an embodiment of the present invention, an "antigen-binding fragment" of an antibody refers to a partial region of the antibody as described above that has antigen-binding ability, and specific examples include F(ab')2, Fab', Fab, Fv (variable fragment of antibody), disulfide-linked Fv, single-chain antibody (scFv), and polymers thereof. Furthermore, antigen-binding fragments include conjugated fragments to which functional molecules other than the anti-RGMa neutralizing antibody of the present application are chemically or genetically engineered, such as non-peptide polymers such as polyethylene glycol (PEG), radioactive substances, toxins, low-molecular-weight compounds, cytokines, growth factors (TGF-β, NGF, Neurotrophin, etc.), albumin, enzymes, and other antibodies.

[0087] "F(ab')2" and "Fab" refer to antibody fragments produced by treating immunoglobulins with protease enzymes such as pepsin or papain, resulting in digestion across the disulfide bond between the two heavy chains in the hinge region. For example, treating IgG with papain results in cleavage upstream of the disulfide bond between the two heavy chains in the hinge region, producing two homologous antibody fragments consisting of a light chain consisting of a VL (light chain variable region) and a CL (light chain constant region), and a heavy chain fragment consisting of a VH (heavy chain variable region) and a CHγ1 (γ1 region of the heavy chain constant region) linked by a disulfide bond at their C-terminal regions. These two homologous antibody fragments are each called Fab. Furthermore, treating IgG with pepsin results in cleavage downstream of the disulfide bond between the two heavy chains in the hinge region, producing an antibody fragment slightly larger than the two Fab fragments linked by the hinge region. This antibody fragment is called F(ab')2.

[0088] <Chimeric Antibody> A preferred embodiment of the anti-RGMa neutralizing antibody of the present invention is a chimeric antibody. Examples of "chimeric antibodies" include chimeric antibodies in which the variable region is derived from immunoglobulin of a non-human animal (mouse, rat, hamster, chicken, etc.) and the constant region is derived from human immunoglobulin. For example, chimeric antibodies can be produced by immunizing a mouse with an antigen, excising the variable region that binds to the antigen from the mouse monoclonal antibody gene, and combining it with an antibody constant region derived from human bone marrow. Constant regions derived from human immunoglobulins have unique amino acid sequences depending on the isotype, such as IgG (IgG1, IgG2, IgG3, IgG4), IgM, IgA (IgA1, IgA2), IgD, and IgE. The constant region of the recombinant chimeric antibody of the present invention may be the constant region of human immunoglobulin belonging to any isotype. Preferably, it is the constant region of human IgG. The gene encoding the chimeric antibody thus prepared can be used to prepare an expression vector, which is then used to transform host cells to obtain transformed cells producing the chimeric antibody.The transformed cells are then cultured to obtain the desired chimeric antibody from the culture supernatant.

[0089] <Humanized Antibody> Another preferred embodiment of the anti-RGMa neutralizing antibody of the present invention is a humanized antibody. The "humanized antibody" of the present invention is an antibody in which only the DNA sequence of the antigen-binding site (CDR; complementarity-determining region) of a non-human animal antibody such as a mouse is grafted onto a human antibody gene (CDR grafting). For example, it can be produced with reference to the methods described in JP-A-4-506458 and Japanese Patent No. 2912618. Specifically, this refers to a humanized antibody in which some or all of its CDRs are CDRs derived from a monoclonal antibody of a non-human mammal (mouse, rat, hamster, etc.), the framework regions of its variable regions are derived from a human immunoglobulin, and its constant regions are derived from a human immunoglobulin.

[0090] The humanized antibody of the present invention can be produced, for example, as follows: However, it goes without saying that the production method is not limited to this.

[0091] For example, a recombinant humanized antibody derived from a mouse monoclonal antibody can be produced by genetic engineering with reference to JP-A-4-506458 and JP-A-62-296890, etc. That is, DNA of the mouse heavy chain CDR region and DNA of the mouse light chain CDR region are isolated from a hybridoma that produces a mouse monoclonal antibody, and a human heavy chain gene covering the entire region excluding the human heavy chain CDR and a human light chain gene covering the entire region excluding the human light chain CDR are isolated from a human immunoglobulin gene.

[0092] The human heavy chain gene grafted with the isolated mouse heavy chain CDR DNA is introduced into an appropriate expression vector so as to be expressible, and similarly, the human light chain gene grafted with the mouse light chain CDR DNA is introduced into another appropriate expression vector so as to be expressible. Alternatively, the human heavy chain and light chain genes grafted with mouse CDRs can be introduced into the same expression vector so as to be expressible. Host cells are transformed with the expression vector prepared in this way to obtain humanized antibody-producing transformants, and the desired humanized antibody is obtained from the culture supernatant by culturing the transformants.

[0093] <Human Antibody> Another preferred embodiment of the anti-RGMa neutralizing antibody of the present invention is a human antibody. A human antibody is an antibody in which all regions constituting the immunoglobulin, including the heavy chain variable region, heavy chain constant region, and light chain variable region, and light chain constant region, are immunoglobulins derived from genes encoding human immunoglobulins, and can be produced by introducing a human antibody gene into a mouse. Specifically, for example, a transgenic animal produced by incorporating at least a human immunoglobulin gene into the gene locus of a non-human mammal such as a mouse can be produced by immunizing the animal with an antigen in the same manner as the above-mentioned method for producing polyclonal or monoclonal antibodies.

[0094] For example, transgenic mice that produce human antibodies can be produced according to the methods described in Nature Genetics, Vol. 7, pp. 13-21, 1994; Nature Genetics, Vol. 15, pp. 146-156, 1997; Published Japanese Translation of PCT International Publication No. H4-504365; Published Japanese Translation of PCT International Publication No. H7-509137; International Publication WO94 / 25585; Nature, Vol. 368, pp. 856-859, 1994; and Published Japanese Translation of PCT International Publication No. H6-500233, etc. More specific examples include HuMab® mice (Medarex, Princeton NJ), KM™ mice (Kirin Pharma Company, Japan), and KM (FCγRIIb-KO) mice.

[0095] Specific examples of anti-RGMa neutralizing antibodies of the present invention include those having a CDR containing a specific amino acid sequence in the heavy chain variable region and a CDR containing a specific amino acid sequence in the light chain variable region (preferably the anti-RGMa neutralizing antibodies (a) to (l) and (a') to (i') above). Note that, as long as the properties of the antibodies of the present invention, such as the ability to bind to RGMa and inhibit (neutralize) RGMa activity, are maintained, the amino acid sequence of the anti-RGMa neutralizing antibodies (preferably the anti-RGMa neutralizing antibodies (a) to (l) and (a') to (i') above) may include substitution, deletion, addition, or insertion of one or several amino acids (1 to 20, 1 to 10, or 1 to 5, preferably 1 or 2). While such substitution, deletion, or addition may be introduced into the CDR, it is preferable that it be introduced into a region other than the CDR. Furthermore, the amino acid substitution is preferably a conservative substitution in order to maintain the properties of the present invention.

[0096] The amino acid sequence of the anti-RGMa neutralizing antibody of the present invention (preferably the anti-RGMa neutralizing antibodies (a) to (l) and (a') to (i') above) containing substitutions, deletions, etc. in the amino acid sequence is, for example, an amino acid sequence in which the heavy chain variable region after amino acid sequence modification has a percent identity of 90% or more (more preferably 95%, 96%, 97%, 98%, 99% or more) with the amino acid sequence before modification, and an amino acid sequence in which the light chain variable region after amino acid sequence modification has a percent identity of 90% or more (more preferably 95%, 96%, 97%, 98%, 99% or more) with the amino acid sequence before modification.

[0097] In the present invention, siRNA refers to a short double-stranded RNA capable of suppressing the expression of a target gene (in the present invention, an RGMa gene). As long as it functions as an siRNA of the present invention that inhibits RGMa activity, the base sequence and length (base length) are not particularly limited; however, they are preferably less than about 30 bases, more preferably about 19 to 27 bases, and even more preferably about 21 to 25 bases. In the present invention, shRNA refers to a single-stranded RNA molecule of about 20 base pairs or more that contains a partially palindromic base sequence, thereby forming a double-stranded structure within the molecule and consisting of a short hairpin structure with an overhang at the 3' end. After being introduced into a cell, such shRNA is degraded to a length of about 20 bases (typically, for example, 21 bases, 22 bases, or 23 bases) within the cell and can suppress the expression of the target gene in the same way as siRNA. In the present invention, the above-mentioned siRNA and shRNA may be in any form as long as they are capable of suppressing the expression of an RGMa gene.

[0098] In the present invention, siRNA or shRNA can be artificially chemically synthesized. Alternatively, antisense and sense RNAs can be synthesized in vitro from template DNA using, for example, T7 RNA polymerase and a T7 promoter. Antisense oligonucleotides may be either DNA or RNA, as long as they are complementary to or hybridize with a sequence of 5 to 100 consecutive bases in the DNA sequence of the RGMa gene. Modifications may also be used as long as they do not impair function. Antisense oligonucleotides can be synthesized by conventional methods, for example, easily using a commercially available DNA synthesizer. Preferred sequences can be selected using conventional selection methods, and the siRNA or shRNA of the present invention can be confirmed by evaluating inhibition of functional RGMa expression.

[0099] <Abnormal Protein Aggregate Accumulation Inhibitor> In an embodiment of the present invention, the abnormal protein aggregate accumulation inhibitor refers to a drug or pharmaceutical composition that has the effect of inhibiting the aggregation of abnormal proteins (misfolded proteins or mutant proteins such as TDP-43, tau, α-synuclein, and SOD1) and the accumulation of the aggregates in cells such as nerve cells. Neurodegenerative diseases that can be treated by the inhibitory effect of the present invention on the accumulation of abnormal protein aggregates are diseases involving the accumulation of abnormal protein aggregates, specifically, diseases such as spinocerebellar degeneration, spinocerebellar ataxia, dentatorubral-pallidoluysian atrophy, fragile X-associated tremor / ataxia syndrome, spinal-bulbar muscular atrophy, fragile X syndrome, fragile XE syndrome, myotonic dystrophy (type 1), fatal insomnia, frontotemporal dementia or frontotemporal lobar degeneration, Pick's disease, primary progressive aphasia, primary progressive non-fluent aphasia, progressive supranuclear palsy, corticobasal degeneration, argyrophilic grain dementia, glial spheroid inclusion tauopathy, and dementia with Lewy bodies. Among these, preferred is frontotemporal dementia (FTD) or frontotemporal lobar degeneration (FTLD).

[0100] <Inhibitor of Abnormal Protein Uptake into Neurons> In an embodiment of the present invention, an inhibitor of abnormal protein uptake into neurons refers to a drug or pharmaceutical composition that inhibits the uptake of abnormal proteins (same meaning as above) present outside neurons. Abnormal proteins taken up into neurons accumulate as intracellular aggregates, resulting in the development of neurodegenerative diseases. Therefore, inhibiting the uptake of abnormal proteins can suppress the accumulation of abnormal protein aggregates within neurons. In the present invention, neurodegenerative diseases that can be treated by inhibiting the uptake of abnormal proteins into neurons include diseases associated with the accumulation of abnormal protein aggregates, as described above. Of these, frontotemporal dementia (FTD) or frontotemporal lobar degeneration (FTLD) is preferred. Furthermore, as shown in the Examples below, RGMa induces the dephosphorylation of cofilin and promotes the depolymerization of filamentous actin (F-actin) to globular actin (G-actin, also known as monomeric actin), thereby increasing the uptake of abnormal proteins (e.g., tau) from outside neurons into the cells. The RGMa inhibitor of the present invention, particularly an anti-RGMa neutralizing antibody, has the effect of inhibiting the depolymerization of filamentous actin to globular actin. Furthermore, the RGMa inhibitor of the present invention, particularly an anti-RGMa neutralizing antibody, has the effect of inhibiting the uptake of abnormal proteins increased by RGMa into neurons by altering such actin dynamics. Due to these effects, the RGMa inhibitor of the present invention, particularly an anti-RGMa neutralizing antibody, exhibits an inhibitory effect on the accumulation of abnormal protein aggregates and can serve as a preventive or therapeutic agent for diseases involving the accumulation of abnormal protein aggregates. Thus, the present invention includes an abnormal protein aggregate accumulation inhibitor that contains an RGMa inhibitor, particularly an anti-RGMa neutralizing antibody, as an active ingredient. The present invention also includes an inhibitor of the uptake of abnormal proteins into neurons that contains an RGMa inhibitor, particularly an anti-RGMa neutralizing antibody, as an active ingredient.Furthermore, the present invention also includes an inhibitor of the depolymerization of filamentous actin to globular actin (preferably, an inhibitor of the depolymerization of filamentous actin to globular actin in nerve cells) that contains an RGMa inhibitor, particularly an anti-RGMa neutralizing antibody, as an active ingredient.

[0101] <Diseases Associated with Accumulation of Abnormal Protein Aggregates> In an embodiment of the present invention, a disease associated with the accumulation of abnormal protein aggregates has the same meaning as the aforementioned disease, and specifically refers to diseases such as spinocerebellar degeneration, spinocerebellar ataxia, dentatorubral-pallidoluysian atrophy, fragile X-associated tremor / ataxia syndrome, spinal-bulbar muscular atrophy, fragile X syndrome, fragile XE syndrome, myotonic dystrophy (type 1), fatal insomnia, frontotemporal dementia or frontotemporal lobar degeneration, Pick's disease, primary progressive aphasia, primary progressive non-fluent aphasia, progressive supranuclear palsy, corticobasal degeneration, argyrophilic grain dementia, glial spheroid inclusion tauopathy, or dementia with Lewy bodies. Among these, preferred is frontotemporal dementia (FTD) or frontotemporal lobar degeneration (FTLD). Thus, the present invention includes a preventive or therapeutic agent for diseases involving the accumulation of abnormal protein aggregates, which contains an RGMa inhibitor, particularly an anti-RGMa neutralizing antibody, as an active ingredient. The present invention also includes a preventive or therapeutic agent for frontotemporal dementia (FTD) or frontotemporal lobar degeneration (FTLD), which contains an RGMa inhibitor, particularly an anti-RGMa neutralizing antibody, as an active ingredient.

[0102] <Pharmaceutical Compositions> The inhibitor of abnormal protein aggregate accumulation or inhibitor of abnormal protein uptake into neurons of the present invention is typically administered systemically or locally, orally or parenterally. The inhibitor of abnormal protein aggregate accumulation or inhibitor of abnormal protein uptake into neurons of the present invention can be formulated by appropriately blending an RGMa inhibitor as an active ingredient with a pharmaceutically acceptable carrier or additive. Pharmaceutical compositions formulated in this manner can be administered orally or parenterally. Specifically, they can be administered in the form of oral preparations such as tablets, coated tablets, pills, powders, granules, capsules, liquids, suspensions, and emulsions, or parenteral preparations such as injections, infusions, suppositories, ointments, and patches. The proportion of carriers or additives may be appropriately determined based on the range commonly used in the pharmaceutical field. The carriers or additives that can be added are not particularly limited, and examples thereof include various carriers such as water, physiological saline, other aqueous solvents, and aqueous or oily bases, as well as various additives such as excipients, binders, pH adjusters, disintegrants, absorption enhancers, lubricants, colorants, flavorings, and fragrances.

[0103] When the RGMa inhibitor is an anti-RGMa neutralizing antibody, a functionally modified antibody thereof, a conjugated antibody thereof, or an antigen-binding fragment thereof, it is preferably administered parenterally, for example, intravenously, intramuscularly, intradermally, intraperitoneally, subcutaneously, or topically, as an injection or infusion formulated with a pharmaceutically acceptable carrier. For example, an injection or infusion containing an anti-RGMa neutralizing antibody can be used as a solution, suspension, or emulsion. Examples of solvents that can be used include distilled water for injection, physiological saline, glucose solution, and isotonic solutions (e.g., solutions of sodium chloride, potassium chloride, glycerin, mannitol, sorbitol, boric acid, borax, propylene glycol, etc.). Furthermore, an injection or infusion containing such an anti-RGMa neutralizing antibody may contain a stabilizer, a solubilizer, a suspending agent, an emulsifier, a soothing agent, a buffer, a preservative, an antiseptic, a pH adjuster, etc. Examples of stabilizers that can be used include albumin, globulin, gelatin, mannitol, glucose, dextran, ethylene glycol, propylene glycol, ascorbic acid, sodium bisulfite, sodium thiosulfate, sodium EDTA, sodium citrate, and dibutylhydroxytoluene. Examples of solubilizing agents that can be used include alcohols (e.g., ethanol), polyalcohols (e.g., propylene glycol, polyethylene glycol), and nonionic surfactants (e.g., Polysorbate 80 (registered trademark), HCO-50, and the like). Examples of suspending agents that can be used include glycerin monostearate, aluminum monostearate, methylcellulose, carboxymethylcellulose, hydroxymethylcellulose, and sodium lauryl sulfate. Examples of emulsifying agents that can be used include gum arabic, sodium alginate, and tragacanth. Examples of soothing agents that can be used include benzyl alcohol, chlorobutanol, and sorbitol. Examples of buffering agents that can be used include phosphate buffer, acetate buffer, borate buffer, carbonate buffer, citrate buffer, and Tris buffer.Examples of preservatives that can be used include methyl parahydroxybenzoate, ethyl parahydroxybenzoate, propyl parahydroxybenzoate, butyl parahydroxybenzoate, chlorobutanol, benzyl alcohol, benzalkonium chloride, sodium dehydroacetate, sodium edetate, boric acid, borax, etc. Examples of antiseptics that can be used include benzalkonium chloride, parahydroxybenzoic acid, chlorobutanol, etc. Examples of pH adjusters that can be used include hydrochloric acid, sodium hydroxide, phosphoric acid, acetic acid, etc.

[0104] When the RGMa inhibitor is a nucleic acid (such as siRNA, shRNA, or an antisense oligonucleotide), it can be administered in the form of a non-viral vector or a viral vector. In the case of a non-viral vector, methods for introducing nucleic acid molecules using liposomes (such as the liposome method, HVJ-liposome method, cationic liposome method, lipofection method, or lipofectamine method), microinjection, or a method for transferring nucleic acid molecules into cells together with a carrier (metal particles) using a gene gun, can be used. For example, when siRNA or shRNA is administered to a living body using a viral vector, viral vectors such as recombinant adenovirus and retrovirus can be used. DNA expressing siRNA or shRNA can be introduced into a DNA or RNA virus such as a detoxified retrovirus, adenovirus, adeno-associated virus, herpesvirus, vaccinia virus, poxvirus, poliovirus, Sindbis virus, Sendai virus, or SV40, and the gene can be introduced into cells or tissues by infecting the cells or tissues with this recombinant virus.

[0105] The formulation obtained in this manner can be administered in an effective amount to, for example, humans or other mammals (e.g., rats, mice, rabbits, sheep, pigs, cattle, cats, dogs, monkeys, etc.) to prevent or treat diseases associated with the accumulation of abnormal protein aggregates. The dosage is determined appropriately taking into consideration the purpose, severity of the disease, the patient's age, weight, sex, medical history, type of active ingredient, etc. For example, when the active ingredient is an anti-RGMa neutralizing antibody, the dosage is preferably approximately 0.02 mg to 4000 mg per day for an average human weighing approximately 65 to 70 kg. The total daily dosage may be a single dose or divided doses.

[0106] The present invention will be described in more detail below with reference to examples, but is not limited to these. In Example 4, an anti-RGMa neutralizing antibody containing the amino acid sequence (b) described herein (SEQ ID NOS: 11-15, and the amino acid sequence of AGS as HCDR3) was used. In the other examples, an anti-RGMa neutralizing antibody containing the amino acid sequence (a) (SEQ ID NOS: 5-10) was used. Palivizumab was used as a control antibody in each example.

[0107] Example 1: Immunohistochemistry of paraffin-embedded sections of the spinal cord of mSOD1 (mutant SOD1) mice. Female G93A mutant transgenic mice (mSOD1 mice) were intraperitoneally administered 250 μg of anti-RGMa neutralizing antibody or control antibody twice weekly from 6 weeks of age until the mice exhibited complete paralysis. mSOD1 mice were euthanized at 105 days of age and perfused with 4% paraformaldehyde (PFA) in PBS. The spinal cords were removed, dehydrated, and embedded in paraffin. The spinal cords were sectioned at 3 μm thickness using a microtome. After deparaffinization and washing with phosphate-buffered saline (PBS), the sections were stained with cresyl violet and the number of motor neurons present in the anterior horn of the spinal cord was counted microscopically using 15 sections per mouse. The results are shown in Figure 1. For immunostaining, deparaffinized sections were incubated with 0.3% hydrogen peroxide for 30 minutes to quench endogenous peroxidase activity, followed by washing with phosphate-buffered saline (PBS). For immunohistochemistry, the primary antibody used was a rabbit antibody against ubiquitin (DAKO), and the secondary antibody was a goat anti-rabbit immunoglobulin conjugated to a peroxidase-conjugated dextran polymer (Dako Envision+, Dako). After 3,3'-diaminobenzidine (DAB) color reaction, the sections were dehydrated, cleared, and mounted. Microscopic images were then taken and the percentage of area showing ubiquitin immunoreactivity in the spinal cord ventral horn was quantified using Image-J. The percentages were compared between mSOD1 mice (n = 7) treated with anti-RGMa neutralizing antibodies and mSOD1 mice (n = 3) treated with a control antibody. The results are shown in Figure 2.

[0108] The number of motor neurons in the ventral horn was increased in the mSOD1 mice treated with anti-RGMa neutralizing antibodies (n = 5) compared with the mSOD1 mice treated with control antibodies (n = 5), and atrophy of motor neurons was observed in the ventral horn of the control-antibody treated mSOD1 mice (Fig. 1). Ubiquitinated aggregated proteins were significantly reduced in the mSOD1 mice treated with anti-RGMa neutralizing antibodies compared with the control-antibody treated group (Fig. 2). These results demonstrate that anti-RGMa neutralizing antibody therapy exerts a protective effect on motor neurons by inhibiting abnormal protein aggregation in the mSOD1 mouse model. The appearance of ubiquitinated aggregated proteins in FTD also indicates that anti-RGMa neutralizing antibodies are effective in the same way as in mSOD1 mice.

[0109] Example 2: Effect on Actin Dynamics RGMa signaling regulates small GTPases, resulting in changes in actin dynamics. Cofilin also induces actin depolymerization, but its effect is abolished upon phosphorylation. The phosphorylation status of cofilin in the spinal cord of mSOD1 mice was examined. mSOD1 mice (n = 5 per group) administered with anti-RGMa neutralizing antibody or control antibody and wild-type mice (WT, n = 4, 105 days old) were perfused with PBS at 4°C. Whole spinal cords were dissected, homogenized on ice, and stored at -80°C. These samples were lysed in RIPA buffer (PBS, 0.1% Triton X-100, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate (SDS), 50 mM Tris-HCl, and 150 mM NaCl, pH 8.0) containing protease and phosphatase inhibitors. Equal concentrations of protein were separated on a 10% SDS-polyacrylamide gel and transferred to a polyvinylidene difluoride (PVDF) membrane. Primary antibodies used were anti-cofilin (1:80,000, Proteintech; 66057-1-Ig) and anti-phospho-cofilin (1:1,000, Cell Signaling; #3313), and the membrane was incubated overnight at 4°C. Subsequently, the membrane was incubated with a peroxidase-conjugated secondary antibody for 90 minutes and visualized using Super Signal West Femto Maximum Sensitivity Substrate (Thermo Fisher Scientific). Images of each band were captured using an Image Gauge (Fuji Film) and analyzed using ImageJ. The results are shown in Figure 3 (A) and (B).

[0110] Next, the state of actin polymerization in the spinal cord was examined. Frozen spinal cord sections from anti-RGMa neutralizing antibody-injected mSOD1 mice (n = 4), control antibody-injected mSOD1 mice (n = 4), and WT mice (n = 3) were fixed in 4% PFA and treated with 0.5% Triton for 15 minutes. After three washes with PBS, sections were incubated overnight at 4°C with rhodamine-conjugated phalloidin (Cytoskeleton, #PHDR1) (1:100). Samples were mounted with Vectashield Mounting Medium (Vector Laboratories, H-1200) containing DAPI. The number of phalloidin-positive cells in both ventral horns was counted using an all-in-one microscope (BZ-X810, Keyence) at 40x magnification. The results are shown in Figure 3(C).

[0111] We also performed studies using primary rat neuronal cultures. Primary cortical neuronal cultures were prepared from 16-day-old Wistar rat embryos. These cells were seeded onto poly-L-lysine (Sigma, P1274-25MG)-coated chamber slides and cultured in high-glucose DMEM supplemented with 5% fetal bovine serum and 100 IU / ml penicillin at 37°C under 5% CO2. The medium was replaced with differentiation medium (Neuro Stem Cell Basal Medium (Merck, SCM003)) supplemented with B-27 (Invitrogen, 12587010), with half of the medium replaced every 2–3 days. After 7 days of culture, the cells were used for evaluation. The effects of RGMa on neuronal filamentous actin (F-actin) and globular actin (G-actin) were evaluated. Cells were treated with recombinant human RGMa (2 μg / ml) (NovoPro, 500040) or double-distilled water (DDW) and anti-RGMa neutralizing or control antibodies (20 μg / ml) for 30 minutes, then fixed with methanol and acetone for 20 minutes at -20°C. F-actin was labeled with rhodamine-conjugated phalloidin (PHDR1) for 40 minutes. After permeabilization with 0.1% TritonX-100 for 5 minutes, G-actin was labeled with Alexa Fluor™ 488-conjugated Dnase1 (D12371) for 20 minutes. Images were acquired using a ZEISS LSM 880 confocal microscope with Airyscan (Az Science). The F-actin / G-actin ratio (F / G ratio) was measured by quantifying the rhodamine and AlexaFluor™ 488 fluorescence intensities of 36 neurons from three independent wells using ImageJ from images acquired with an all-in-one fluorescence microscope (BZ-X800, Keyence). The results are shown in Figure 4(A).

[0112] Cofilin dephosphorylation was significantly increased in the spinal cord of mSOD1 mice, which was inhibited by anti-RGMa neutralizing antibodies (Fig. 3(A) and (B)). F-actin staining revealed increased actin depolymerization in the spinal cord of mSOD1 mice, which was inhibited by anti-RGMa neutralizing antibodies (Fig. 3(C)). In rat primary neuronal cultures, the addition of RGMa decreased the F / G ratio, and this effect was inhibited by anti-RGMa neutralizing antibodies (Fig. 4(A)). These results demonstrate that RGMa signaling promotes actin depolymerization via cofilin dephosphorylation, and that anti-RGMa neutralizing antibodies inhibit these effects.

[0113] Example 3: Effect on the uptake of aggregated proteins from extracellular sources into cells. This study was conducted using primary rat neuronal cultures in the same manner as described above. (1) Intracellular uptake of mutant proteins via RGMa-mediated actin signaling. The effect of Jasplakinolide (AdipoGen Life Sciences, AG-CN2-0037), an inhibitor of actin depolymerization, on the uptake of mutant proteins by RGMa was examined. First, FLAG-tagged recombinant SOD1 proteins (G93A, A4V) were purified. Recombinant human RGMa (2 μg / ml) or double-distilled water (DDW) and Jasplakinolide (250 nM) or DMSO were added to primary rat cortical neurons and incubated for 30 minutes. Then, mutant SOD1 proteins (G93A, A4V) were added at 250 ng / ml. After 1 hour, the cells were fixed with methanol / acetone and labeled with FITC-conjugated mouse monoclonal anti-FLAG M2 antibody (Sigma-Aldrich, F4049). Images were acquired with an inverted confocal laser scanning microscope (FV3000, Olympus), and the mean FITC fluorescence intensity of 36 neurons from three independent wells was calculated using ImageJ. The results are shown in Figure 4(B).

[0114] (2) Effect of anti-RGMa neutralizing antibodies on cellular uptake of mutant proteins. We investigated whether anti-RGMa neutralizing antibodies inhibited RGMa-mediated cellular uptake of mutant proteins. Recombinant human RGMa (2 μg / ml), anti-RGMa neutralizing antibodies, or control antibodies (20 μg / ml) were mixed with recombinant FLAG-tagged proteins (250 ng / ml) of G93A mutant SOD1, A4V mutant SOD1, or wild-type SOD1. The mixture was added to primary rat cortical neurons, incubated for 60 minutes, and then fixed with methanol and acetone at −20°C for 20 minutes. The cells were labeled with FITC-conjugated mouse monoclonal anti-FLAG M2 antibody (Sigma-Aldrich, F4049). Images were acquired using an inverted confocal laser scanning microscope (Olympus FV3000) and the mean FITC fluorescence intensity of 36 neurons from three independent wells was calculated using ImageJ. The results are shown in Figure 5. Similar experiments were performed using dextran (pHrodo™ Red Dextran, Invitrogen, P10361) instead of the mutant proteins. Cells were incubated with dextran for 10 minutes. The results are shown in Figure 6. For tau, rat primary cortical neurons were treated with recombinant human RGMa (2 μg / ml) and anti-RGMa neutralizing or control antibodies (20 μg / ml), then incubated with recombinant human tau protein (AnaSpec, AS-55556-50) for 60 minutes and then fixed with methanol and acetone at -20°C for 20 minutes. Cells were labeled with a mouse monoclonal anti-phosphorylated tau antibody (Invitrogen MN1020 1:100) overnight at 4°C and then stained with Alexa Fluor™ 594. The specimens were mounted using a mounting medium containing DAPI (Vector Laboratories, VECTASHIELD Mounting Medium H-1200) and images were acquired using an inverted confocal laser scanning microscope FV3000 (Olympus). The mean fluorescence intensity of 36 neurons from two independent wells was calculated using ImageJ. The results are shown in Figure 7.

[0115] The addition of RGMa also increased the cellular uptake of G93A and A4V mutant SOD1 proteins, an effect that was inhibited by jasplakinolide. These results suggest that RGMa promotes the cellular uptake of mutant proteins by actin depolymerization. In the presence of recombinant human RGMa, the cellular uptake of G93A and A4V mutant SOD1 proteins was significantly reduced in cells treated with anti-RGMa neutralizing antibodies compared to cells treated with control antibodies (Fig. 5). When wild-type SOD1 protein was used, no increase in cellular uptake was observed with the addition of RGMa (Fig. 4(B)). Furthermore, stimulation with dextran for 10 minutes yielded results similar to those observed with mutant SOD1 proteins (Fig. 6). The addition of recombinant human RGMa also increased the cellular uptake of recombinant human tau protein. In cells treated with anti-RGMa neutralizing antibodies in the presence of recombinant human RGMa, tau protein uptake was significantly reduced compared to cells treated with control antibodies (Figure 7). These results demonstrate that RGMa promotes the internalization of extracellular abnormal proteins into neurons, and that anti-RGMa neutralizing antibodies exert their effects by inhibiting this process. These results demonstrate that RGMa promotes the internalization of extracellular abnormal proteins by altering actin dynamics in neurons, and that anti-RGMa neutralizing antibodies exert their effects by inhibiting this process. Since tau and other proteins disseminate between cells in FTD, this indicates that anti-RGMa neutralizing antibodies are also effective.

[0116] Example 4: Effect of anti-RGMa neutralizing antibodies on TDP-43 aggregation in mPFN1 (mutant PFN1) mice. G118V mutant profilin1-transduced mice (mPFN1 mice) were used as a mouse model of TDP-43 aggregation. mPFN1 mice are known to exhibit abnormal TDP-43 aggregation in neurons. mPFN1 mice were intraperitoneally administered anti-RGMa neutralizing antibodies or negative control antibodies at a dose of 10 mg / kg twice weekly from 100 days of age. Terminally ill mPFN1 mice were euthanized and perfused with 4% paraformaldehyde (PFA) in PBS. Their spinal cords were then dehydrated and embedded in paraffin. Spinal cords were sectioned at 3 μm thickness using a microtome. Because TDP-43 accumulates in the cytoplasm following phosphorylation, TDP-43 aggregation within neurons was detected by immunohistochemical staining of phosphorylated TDP-43. Deparaffinized sections were subjected to antigen retrieval by microwave irradiation in 10 mM citrate buffer. Endogenous peroxidase activity was quenched by incubation with 0.3% hydrogen peroxide for 30 minutes, followed by washing with phosphate-buffered saline (PBS). The primary antibody was a rabbit antibody against phosphorylated TDP-43 (Proteintech), and the secondary antibody was a goat anti-rabbit immunoglobulin conjugated to a peroxidase-conjugated dextran polymer (Dako Envision+, Dako). After 3,3'-diaminobenzidine (DAB) color reaction, sections were dehydrated, cleared, and mounted. After microscopic imaging, a blinded evaluator visually counted the percentage of spinal cord anterior horn cells positive for phosphorylated TDP-43 in the cytoplasm and compared the percentages between two mPFN1 mice treated with anti-RGMa neutralizing antibodies and three mPFN1 mice treated with a control antibody. The results are shown in Figure 8.

[0117] The number of cells expressing cytoplasmic phosphorylated TDP-43 in the spinal ventral horn of mPFN1 mice treated with anti-RGMa neutralizing antibodies was significantly reduced compared to the control group (Figure 8). These results demonstrate that anti-RGMa neutralizing antibody therapy inhibits TDP-43 aggregation. The appearance of TDP-43 aggregated proteins in FTD also demonstrates the efficacy of anti-RGMa neutralizing antibodies, as in mPFN1 mice.

[0118] Example 5: Evaluation Using Clinical Samples (Measurement of RGMa in CSF) Cerebrospinal fluid (CSF) samples were collected from nine FTD patients and control subjects (32 patients with other neurodegenerative diseases (OND) and 24 patients with non-neurodegenerative diseases (ND)) and immediately centrifuged at 400 g for 10 minutes at 4°C. The CSF supernatant was stored at -80°C until use. Patients with other neurodegenerative diseases (OND) included patients with multiple sclerosis, neuromyelitis optica, Parkinson's disease, chronic inflammatory demyelinating polyneuropathy, and cervical spondylosis. Patients with non-neurodegenerative diseases (ND) included patients with normal pressure hydrocephalus, muscle diseases, peripheral nerve diseases, and dissociative disorders. The concentration of soluble RGMa in CSF was measured using an enzyme-linked immunosorbent assay (ELISA) kit (R&D Systems). The results are shown in Figure 9. Soluble RGMa in CSF from FTD patients was significantly elevated compared with non-neurodegenerative disease patients (ND) and other neurodegenerative disease patients (OND). These data indicate that RGMa is elevated in the CSF of FTD patients and contributes to the pathology of FTD.

[0119] <Explanation of the sequence listing> SEQ ID NO: 1: Amino acid sequence of human RGMa precursor protein SEQ ID NO: 2: Amino acid sequence of mouse RGMa precursor protein SEQ ID NO: 3: Amino acid sequence of rat RGMa precursor protein SEQ ID NO: 4: DNA sequence of human RGMa gene SEQ ID NO: 5: Amino acid sequence of LCDR1 of anti-RGMa neutralizing antibody r116A3 SEQ ID NO: 6: Amino acid sequence of LCDR2 of anti-RGMa neutralizing antibody r116A3 SEQ ID NO: 7: Amino acid sequence of LCDR3 of anti-RGMa neutralizing antibody r116A3 SEQ ID NO: 8: Amino acid sequence of HCDR1 of anti-RGMa neutralizing antibody r116A3 SEQ ID NO: 9: Amino acid sequence of HCDR2 of anti-RGMa neutralizing antibody r116A3 SEQ ID NO: 10: Amino acid sequence of HCDR3 of anti-RGMa neutralizing antibody r116A3 SEQ ID NO: 11: Amino acid sequence of LCDR1 of anti-RGMa neutralizing antibody r70E4 SEQ ID NO: 12: Amino acid sequence of LCDR2 of anti-RGMa neutralizing antibody r70E4 SEQ ID NO: 13: Amino acid sequence of LCDR3 of anti-RGMa neutralizing antibody r70E4 SEQ ID NO: 14: Amino acid sequence of HCDR1 of anti-RGMa neutralizing antibody r70E4 SEQ ID NO: 15: Amino acid sequence of HCDR2 of anti-RGMa neutralizing antibody r70E4 SEQ ID NO: 16: Amino acid sequence of human RGMa epitope SEQ ID NO: 17: Amino acid sequence of LCDR1 of anti-RGMa neutralizing antibody 5F9 SEQ ID NO: 18: Amino acid sequence of LCDR2 of anti-RGMa neutralizing antibody 5F9 SEQ ID NO: 19: Amino acid sequence of LCDR3 of anti-RGMa neutralizing antibody 5F9 SEQ ID NO: 20: Amino acid sequence of HCDR1 of anti-RGMa neutralizing antibody 5F9 SEQ ID NO: 21: Amino acid sequence of HCDR2 of anti-RGMa neutralizing antibody 5F9 SEQ ID NO: 22: Amino acid sequence of HCDR3 of anti-RGMa neutralizing antibody 5F9 SEQ ID NO: 23: Amino acid sequence of LCDR1 of anti-RGMa neutralizing antibody 8D1 SEQ ID NO: 24: Amino acid sequence of LCDR2 of anti-RGMa neutralizing antibody 8D1 SEQ ID NO: 25: Amino acid sequence of LCDR3 of anti-RGMa neutralizing antibody 8D1 SEQ ID NO: 26: Amino acid sequence of HCDR1 of anti-RGMa neutralizing antibody 8D1 SEQ ID NO: 27: Amino acid sequence of HCDR2 of anti-RGMa neutralizing antibody 8D1 SEQ ID NO: 28: Amino acid sequence of HCDR3 of anti-RGMa neutralizing antibody 8D1 SEQ ID NO: 29: Amino acid sequence of LCDR1 of anti-RGMa neutralizing antibody AE12-1SEQ ID NO: 30: Amino acid sequence of LCDR2 of anti-RGMa neutralizing antibody AE12-1 SEQ ID NO: 31: Amino acid sequence of LCDR3 of anti-RGMa neutralizing antibody AE12-1 SEQ ID NO: 32: Amino acid sequence of HCDR1 of anti-RGMa neutralizing antibody AE12-1 SEQ ID NO: 33: Amino acid sequence of HCDR2 of anti-RGMa neutralizing antibody AE12-1 SEQ ID NO: 34: Amino acid sequence of HCDR3 of anti-RGMa neutralizing antibody AE12-1 SEQ ID NO: 35: Amino acid sequence of LCDR3 of anti-RGMa neutralizing antibody AE12-1Y SEQ ID NO: 36: Amino acid sequence of epitope of human RGMa SEQ ID NO: 37: Amino acid sequence of epitope of human RGMa SEQ ID NO: 38: Amino acid sequence of epitope of human RGMa SEQ ID NO: 39: Amino acid sequence of epitope of human RGMa SEQ ID NO: 40: Amino acid sequence of LCDR3 of anti-RGMa neutralizing antibody AE12-1F SEQ ID NO: 41: Amino acid sequence of LCDR3 of anti-RGMa neutralizing antibody AE12-1H SEQ ID NO: 42: Amino acid sequence of LCDR3 of anti-RGMa neutralizing antibody AE12-1L SEQ ID NO: 43: Amino acid sequence of LCDR3 of anti-RGMa neutralizing antibody AE12-1V SEQ ID NO: 44: Amino acid sequence of LCDR3 of anti-RGMa neutralizing antibody AE12-1I SEQ ID NO: 45: Amino acid sequence of LCDR3 of anti-RGMa neutralizing antibody AE12-1K SEQ ID NO: 46: Amino acid sequence of the light chain variable region of anti-RGMa neutralizing antibody r116A3 (humanized antibody) SEQ ID NO: 47: Amino acid sequence of the heavy chain variable region of anti-RGMa neutralizing antibody r116A3 (humanized antibody) SEQ ID NO: 48: Light chain amino acid sequence of anti-RGMa neutralizing antibody r116A3 (humanized antibody) SEQ ID NO: 49: Heavy chain amino acid sequence of anti-RGMa neutralizing antibody r116A3 (humanized antibody) SEQ ID NO: 50: Amino acid sequence of the light chain variable region of anti-RGMa neutralizing antibody r70E4 SEQ ID NO: 51: Amino acid sequence of the heavy chain variable region of anti-RGMa neutralizing antibody r70E4 SEQ ID NO: 52: Light chain amino acid sequence of anti-RGMa neutralizing antibody r70E4 SEQ ID NO: 53: Heavy chain amino acid sequence of anti-RGMa neutralizing antibody r70E4 SEQ ID NO: 54: Amino acid sequence of the light chain variable region of anti-RGMa neutralizing antibody 5F9 SEQ ID NO: 55: Amino acid sequence of the heavy chain variable region of anti-RGMa neutralizing antibody 5F9 SEQ ID NO: 56: Amino acid sequence of the light chain variable region of anti-RGMa neutralizing antibody 8D1SEQ ID NO: 57: Amino acid sequence of the heavy chain variable region of anti-RGMa neutralizing antibody 8D1 SEQ ID NO: 58: Amino acid sequence of the light chain variable region of anti-RGMa neutralizing antibody AE12-1 SEQ ID NO: 59: Amino acid sequence of the heavy chain variable region of anti-RGMa neutralizing antibody AE12-1 SEQ ID NO: 60: Amino acid sequence of the light chain variable region of anti-RGMa neutralizing antibody AE12-1Y SEQ ID NO: 61: Light chain amino acid sequence of anti-RGMa neutralizing antibody AE12-1Y-QL SEQ ID NO: 62: Heavy chain amino acid sequence of anti-RGMa neutralizing antibody AE12-1Y-QL

[0120] The present invention is expected to be useful in the prevention or treatment of diseases involving the accumulation of abnormal protein aggregates, as RGMa inhibitors have the effect of suppressing the accumulation of abnormal protein aggregates or inhibiting the uptake of abnormal proteins into nerve cells, and have great utility in the pharmaceutical industry.

Claims

1. An inhibitor of the accumulation of abnormal protein aggregates, containing an RGMa inhibitor as an active ingredient.

2. An inhibitor of the uptake of abnormal proteins into nerve cells, containing an RGMa inhibitor as its active ingredient.

3. The agent according to claim 1 or 2, wherein the agent for suppressing the accumulation of abnormal protein aggregates or the agent for inhibiting the uptake of abnormal proteins into nerve cells is an agent for preventing or treating a disease associated with the accumulation of abnormal protein aggregates.

4. The agent according to claim 3, wherein the disease involving the accumulation of abnormal protein aggregates is selected from spinocerebellar degeneration, spinocerebellar ataxia, dentatorubral-pallidoluysian atrophy, fragile X-associated tremor / ataxia syndrome, spinal-bulbar muscular atrophy, fragile X syndrome, fragile XE syndrome, myotonic dystrophy (type 1), fatal insomnia, frontotemporal dementia or frontotemporal lobar degeneration, Pick's disease, primary progressive aphasia, primary progressive non-fluent aphasia, progressive supranuclear palsy, corticobasal degeneration, argyrophilic grain dementia, glial spheroid inclusion tauopathy, and dementia with Lewy bodies.

5. The agent described in claim 3 or 4, wherein the disease associated with the accumulation of abnormal protein aggregates is frontotemporal dementia (FTD) or frontotemporal lobar degeneration (FTLD).

6. The agent according to any one of claims 1 to 5, wherein the RGMa inhibitor is an anti-RGMa neutralizing antibody.

7. The agent according to claim 6, wherein the anti-RGMa neutralizing antibody is a humanized antibody.

8. The agent described in claim 6 or 7, wherein the anti-RGMa neutralizing antibody is an antibody that recognizes an amino acid sequence selected from SEQ ID NO: 16, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38 and SEQ ID NO:

39.

9. An anti-RGMa neutralizing antibody comprising any one of the following (a) to (l): (a) an anti-RGMa neutralizing antibody comprising a light chain variable region comprising an LCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 5, an LCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 6, and an LCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 7, and a heavy chain variable region comprising an HCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 8, an HCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 9, and an HCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 10; (b) an anti-RGMa neutralizing antibody comprising a light chain variable region comprising an LCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 11, an LCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 12, and an LCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 13, and a heavy chain variable region comprising an HCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 14, an HCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 15, and an HCDR3 comprising SFG in its amino acid sequence; (c) an anti-RGMa neutralizing antibody comprising a light chain variable region comprising an LCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 17, an LCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 18, and an LCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 19, and a heavy chain variable region comprising an HCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 20, an HCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 21, and an HCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 22; (d) an anti-RGMa neutralizing antibody comprising a light chain variable region comprising an LCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 23, an LCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 24, and an LCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 25, and a heavy chain variable region comprising an HCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 26, an HCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 27, and an HCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 28; (e) an anti-RGMa neutralizing antibody comprising a light chain variable region comprising LCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 29, LCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 30, and LCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 31, and a heavy chain variable region comprising HCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 32, HCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 33, and HCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 34;(f) an anti-RGMa neutralizing antibody comprising a light chain variable region comprising LCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 29, LCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 30, and LCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 35, and a heavy chain variable region comprising HCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 32, HCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 33, and HCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 34; (g) an anti-RGMa neutralizing antibody comprising a light chain variable region comprising LCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 29, LCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 30, and LCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 40, and a heavy chain variable region comprising HCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 32, HCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 33, and HCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 34; (h) an anti-RGMa neutralizing antibody comprising a light chain variable region comprising LCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 29, LCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 30, and LCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 41, and a heavy chain variable region comprising HCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 32, HCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 33, and HCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 34; (i) an anti-RGMa neutralizing antibody comprising a light chain variable region comprising LCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 29, LCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 30, and LCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 42, and a heavy chain variable region comprising HCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 32, HCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 33, and HCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 34; (j) an anti-RGMa neutralizing antibody comprising a light chain variable region comprising LCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 29, LCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 30, and LCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 43, and a heavy chain variable region comprising HCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 32, HCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 33, and HCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 34;(k) an anti-RGMa neutralizing antibody comprising a light chain variable region comprising an LCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 29, an LCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 30, and an LCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 44, and a heavy chain variable region comprising an HCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 32, an HCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 33, and an HCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 34; and (l) an anti-RGMa neutralizing antibody comprising a light chain variable region comprising an LCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 29, an LCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 30, and an LCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 45, and a heavy chain variable region comprising an HCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 32, an HCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 33, and an HCDR3 comprising the amino acid sequence set forth in SEQ ID NO:

34.

10. A method for preventing or treating a disease associated with the accumulation of abnormal protein aggregates, comprising administering an effective amount of an RGMa inhibitor to a mammal in need of treatment.

11. The method for prevention or treatment according to claim 10, wherein the RGMa inhibitor is an anti-RGMa neutralizing antibody.

12. Use of an RGMa inhibitor for the manufacture of an agent for the prevention or treatment of a disease associated with the accumulation of abnormal protein aggregates.

13. The use according to claim 12, wherein the RGMa inhibitor is an anti-RGMa neutralizing antibody.